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ABSTRACT 
The β-site APP cleaving enzyme-1 (BACE1) is a transmembrane aspartic protease produced in 
humans, being most active in the human brain. BACE1 is heavily implicated in the Alzheimer’s 
disease pathology where it mediates the rate-limiting step in the production of amyloid-β 
peptide. Expression and purification of BACE1 is associated with low yields due to aggregation 
as a result of its inherent insolubility. In this study, expression of a recombinant form of BACE1 
in Escherichia coli is described. This expression was successfully optimized to generate yields 
of 12 mg/L of culture, with the optimized protocol involving induction using 1 mM IPTG in 
the presence of 1% ethanol overnight at 16 ˚C. The expressed protein was demonstrated to be 
insoluble after induction and was resolubilized and refolded using a 24-hour incubation in a 
10% N-lauryl sarcosine sodium salt solution. Refolding was confirmed through the use of a 
gelatine gel zymogram which indicated that the protein was catalytically active. The use of 
gelatine gel zymograms for assessment of BACE1 activity have not previously been described 
in literature. The purified recombinant BACE1 was confirmed to be immunogenic in chickens 
with the purified antibodies being capable of successfully detecting BACE1 produced in 
mammalian cells. A differential scanning fluorimetry (DSF) assay was then optimized using 
the recombinant BACE1, in an effort to screen for BACE1 binding compounds. The DSF assay 
was carried out in phosphate buffered saline (PBS), pH 7.4 at a concentration of 1 µM with the 
unfolding being confirmed to occur without the formation of a defined unfolding intermediate, 
exhibiting a melting temperature (Tm) of 82 ± 0.21°C. The standard Gibbs free energy, entropy 
and enthalpy of unfolding of BACE1 in PBS were calculated to be 112 ± 0.1 kJ/mol, 1.82 ± 
0.002 kJ/mol K and 642 ± 0.7 kJ/mol respectively. In the presence of the BACE1 specific 
inhibitor, Verubecestat, the Tm rose to 84.15 ± 0.28°C. An in-house compound library derived 
from the ChemBridge DiverSet compound library was then screened against BACE1 using this 
DSF assay. Three compounds were found to induce a thermal shift, indicating binding. These 
compounds were N-ethyl-N',N'-dimethyl-N-[2-(trifluoromethyl)benzyl]-1,2-ethanediamine 
(C19) displaying a ∆Tm of 2.4 0.65 ˚C, 3-cyclopentyl-N-(4-pyridinylmethyl)propanamide 
(C34) with a ∆Tm of 3.045 ± 0.66 ˚C and 4-chloro-1-(2-ethoxybenzoyl)-1H-pyrazole (C39) 
with a ∆Tm  of 2.625 ± 0.64 ˚C. The in-house compound library was also screened, in silico, 
against a 3D BACE1 model which illustrated that both C19 and C34 docked to the catalytic 
residues of BACE1. It was established that C19 likely bound a non-catalytic binding site as 
well. No appreciable docking was detected for the C39 compound in silico however, indicating 
the possibility of an undetected binding site. Using a BACE2 in silico model, the specificity of 
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C34 for BACE1 over BACE2 was also predicted. Intracellular BACE1 binding capability of 
each test compound was assessed through the first reported use of a cellular thermal shift assay 
for screening for BACE1 binding compounds. The cellular thermal shift assay was carried out 
using the known BACE1 inhibitor Verubecestat, where an increase in Tagg to 53.27 ± 0.89°C 
from 49.53 ± 0.69°C was observed. The three test compounds were then screened with C34 
yielding a significant increase in Tagg (p-value < 0.05) from 53.09 ± 1.30 confirming 
intracellular binding. Compound C34 was then used in an iterative screening of the Enamine 
Real compound database for compound analogues using the in silico BACE1 model, ultimately 
resulting in the identification of compound C5064. Compound C5064 was detected to bind to 
the BACE1 catalytic site yielding a Glide score of -10.121. The cellular thermal shift assay was 
again used, confirming C5064 possessed the ability to bind intracellular BACE, resulting in the 
second novel intracellular BACE1 binding molecule identified in this study. Finally, a zebrafish 
embryo toxicity test was carried out with C19, C34 and C39 generating LC50 values of 26.125 
± 2.45, 127 ± 9.9 and 4.52 ± 0.61 µM respectively. Only C34 was detected to be teratogenic 
yielding a teratogenicity index of 1.33. No LC50 concentration or teratogenicity index was 
calculated for compound C5064 however, due to the compound exhibiting no lethality within 
its solubility range. This study succeeded in thoroughly assessing the thermostability of 
BACE1, both recombinantly expressed in Escherichia coli as well as in mammalian human 
embryonic kidney-293 cells. Four novel BACE1 binding compounds were detected with two 
confirmed to bind BACE1 intracellularly, with the first cellular thermal shift assay carried out 
on BACE1 being reported. Finally, all test compounds were successfully assessed for toxicity 
and teratogenicity in vivo using a zebrafish embryo toxicity test. 
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CHAPTER 1: LITERATURE REVIEW 
1.1 Introduction 
 
The first description of Alzheimer’s disease (AD) was made by the German psychiatrist Alois 
Alzheimer in a lecture delivered in 1906. Here he described a disease he had noticed in a 55-
year-old patient, which resulted in cognitive decline followed by death. It was discovered 
through post-mortem examination that senile amyloid plaques, alongside neurofibrillary tangles 
(NFT), were present in the brain of the patient. Up until then senile plaques had only been 
documented in the elderly, while the NFTs were a novel discovery at the time. Alzheimer would 
publish an article describing this briefly in 1907 and later again in 1911 in which he further 
elucidated on his findings (Alzheimer, 1907, Alzheimer, 1911). 
 
It was only in 1984 however, that the first successful purification of the amyloid protein which 
comprises senile plaques was carried out by Glenner and Wong (Glenner and Wong, 1984). 
The peptide was designated amyloid-β (Aβ) due to its β-pleated sheet structure. Description of 
the composition of NFTs followed and in 1986 it was reported, through the use of antibodies 
raised against NFTs, that the microtubule-associated tau protein was a major component 
thereof, with ubiquitin being another (Nukina and Ihara, 1986; Mori et al., 1987). After the first 
successful production of cDNA encoding the amyloid precursor protein (APP) gene in 1987, 
several gene mutations were associated with AD susceptibility (Kang et al., 1987). These 
mutations were found in genes for presenilin, APP, as well as apolipoprotein E4 (Corder et al., 
1993, Citron et al., 1992, Sherrington et al., 1996). In 1993 the first drug against AD was 
approved by the Food and Drug Administration of the United States of America (FDA). Since 
then only four other treatments have been approved for commercial use against AD. AD is 
currently the most common form of dementia (Sardana et al., 2003). AD susceptibility has been 
correlated most strongly with age, however it has also been linked to various lifestyle choices 
such as smoking and poor diet (Ott et al., 1998; Engelhart et al., 2012). 
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1.2 Pathophysiology of Alzheimer’s disease 
1.2.1 Amyloid hypothesis pathology 
The broad pathophysiology of AD involves four major pathways (Cole and Vassar, 2007). 
Namely the amyloid, tau, cholinergic and inflammatory pathways, each of which is implicated 
in the characteristic cognitive decline in AD (Kar et al., 2002; Gong and Iqbal, 2008). 
According to the amyloid hypothesis, Aβ plays a role in initiating all four pathways. The 
hypothesis proposes that when a neuron generates excess Aβ, this Aβ will bind to the α-7 
nicotinic receptors on neighbouring astrocytes (Pirttimaki et al., 2013). This binding action 
induces the secretion of glutamateviaexocytosis, which in turn binds to N-Methyl-D-aspartate 
receptors (NMDARs) found on the original neuron, which results in an uptake of Ca2+ ions into 
the cell (Shankar et al., 2007). The imbalance in Ca2+ ions causes mitochondria to release 
reactive oxygen species (ROS) which bring about oxidative stress (Reynolds and Hastings, 
1995). Both the influx of calcium as well as the oxidative stress are thought to dissociate tau 
from the neurons microtubules, allowing for its hyperphosphorylation by various kinases (Su 
et al., 2010) (Mattson et al., 1991). The hyperphosphorylated tau then aggregates inside the 
neuron forming NFTs (Nukina and Ihara, 1986). These NFTs cause cellular damage through 
actin destabilization, mitochondrial damage as well as through reducing the ability of a neuron 
to transfer neurotransmitters through synapses (Kraemer et al., 2003). The tau oligomers that 
form these NFTs also spread to other neurons through synapses, after which they interact with 
unaltered tau converting it into its amyloid-like form (Guo and Lee, 2011). Excess Aβ also 
forms extracellular plaques which induce inflammation through the action of microglia (Sasaki 
et al., 2002). This pro-inflammatory response of microglia to Aβ plaques results in the secretion 
of ROS, as well as several inflammatory cytokines such as interleukin-1β, tumour necrosis 
factor α and interferon γ (Wilkinson and Landreth, 2006; Wang et al., 2015). The resulting 
combination of NFTs, Ca2+ imbalance, inflammation and amyloid load results in a proliferative 
cycle, causing neurodegeneration in the process. This damage to neurons results in cognitive 
decline, most notably when cholinergic neurons are damaged as this disrupts the brains ability 
to produce the neurotransmitter acetylcholine, which plays roles in memory and learning 
(Rasool et al., 1986). This deficit of acetylcholine is further compounded by the ability of Aβ 
to induce acetylcholine degradationviacholinesterase enzymes (Kumar et al., 2018). 
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1.2.2 Concerns regarding the amyloid hypothesis 
The amyloid hypothesis is complicated by the identification that amyloid plaques are present 
in 20-40% of the elderly population that do not suffer from the disease and often in high enough 
amounts so as to warrant an AD diagnosis (Drachman, 2014). Originally it was assumed that at 
a certain level of amyloid burden the cognitive decline was induced, however the fact that such 
large portions of the elderly population exhibit high amyloid load without Alzheimer’s 
symptoms made this appear unlikely. Further, it is difficult to determine whether in these cases 
the symptoms simply have yet to present themselves, as this would require constant mental 
evaluation (Kepp, 2016). The amyloid hypothesis was altered to accommodate this based on 
the presence of various subtypes of the Aβ peptide, most important of which are the Aβ40 and 
Aβ42. The modified amyloid hypothesis now assumes that, rather than an overall Aβ load 
causing cognitive decline, it is, in fact, the ratio between these two forms of the Aβ peptide that 
instigates it, a theory supported by the knowledge that Aβ42 is substantially more toxic than 
Aβ4. This is further supported by the fact that several presenilin mutations affect this ratio and 
have indeed been correlated to the onset of AD (Tiwari and Kepp, 2015). There still remains 
however, speculation around how exactly this ratio results in the cognitive decline. Another 
area where further research is required involves the location at which the amyloid plaques 
occur. AD is associated with degradation of specific regions of the brain, most notably the 
hippocampus and amygdala, whereas the location of amyloid plaques do not correspond as they 
are often distributed across the entire brain before AD symptoms present themselves (Kepp, 
2016). This, along with the knowledge that level of amyloid load has not been correlated to 
cognitive decline causes concern for this theory (Drachman, 2014). 
1.2.3 Generation of amyloid-β 
The Aβ peptide is generated from the sequential cleavage of APP, it can however be cleaved 
through one of two pathways, the amyloidogenic and non-amyloidogenic pathways, 
summarized in Figure 1.1. In the non-amyloidogenic pathway, APP is cleaved by a group of 
proteases, known as α-secretases, which includes the enzymes, a disintegrin and 
metalloproteinase domain-containing proteins 9, 10 and 17 (ADAM9, ADAM10 and ADAM17 
respectively) with ADAM10 being the primary α-secretase (Kuhn et al., 2010). This occurs on 
the cell surface. In the amyloidogenic pathway, as shown in Figure 1.1, APP is cleaved 
sequentially by two enzymes. First the β-secretase, an aspartic protease named β-site APP 
cleaving enzyme-1 (BACE1) cleaves the APP at its β-cleavage site (Cai et al., 2001). This 
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typically occurs in the endosomes and Golgi apparatus after APP is internalized into the cell 
and results in two products, namely secreted β-amyloid precursor protein (sAPPβ) and C99 
(Yan, 2017). The transmembrane C99 is then cleaved by the protein complex ɣ-secretase 
comprised of presenilin 1 or 2, nicastrin, presenilin enhancer-2 and anterior pharynx defective-
1  (Zhang et al., 2001; Esler et al., 2002; Kimberly et al., 2003). This results in the formation 
of the APP intracellular domain (AICD) as well as the Aβ peptide. 
 
 
Figure 1.1: The diverging pathways of amyloid precursor protein (APP) processing by the secretase-class 
enzymes. APP contains three cleavage sites, each of which is recognized by either β, α or ɣ-secretase. In the 
amyloidogenic pathway, the β-secretase, β-site APP cleaving enzyme-1 (BACE1), cleaves APP first, at the β-
cleavage site producing secreted β-amyloid precursor protein (sAPPβ) and C99. After this, the ɣ-secretase complex 
cleaves the C99 peptide into either Amyloid β (Aβ) and the APP intracellular domain (AICD). In the non-
amyloidogenic pathway, α-secretase cleaves APP, first generating secreted α-amyloid precursor protein (sAPPα) 
and C83, after which, ɣ-secretase cleaves the C83 peptide into the peptide p3 and AICD. Adapted from Prete et 
al., 2014. 
1.2.4 Intervention strategies 
Some attempts have been made, in mouse models to modulate the activity of the α-secretase 
enzymes in order to reduce the amount of Aβ peptide being produced (Postina et al., 2004). 
Through this, overexpression of ADAM10 resulted in the majority of APP being processed in 
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the non-amyloidogenic pathway which resulted in a decrease in cognitive decline. Although no 
clinical trials have as of yet been carried out, it was described in 2018 that the compound 
cosmosiin increased ADAM10 expression in neuroblastoma cells (Min et al., 2018). With 
regards to direct inhibition of the amyloidogenic pathway, ɣ-secretase inhibition was a possible 
target. Side-effects of its inhibition are of concern with regards to human treatment, as the 
complex is known to process not only APP but also mediate the cleavage of proteins such as 
Notch, E-cadherin and CD44 (Marambaud et al., 2002; Kimberly et al., 2003; Murakami et al., 
2003). This problem was highlighted in the trials of Semagacestat, the ɣ-secretase inhibitor 
from Eli Lilly (Hopkins, 2011). Inhibition of the ɣ-secretase enzyme resulted in increased 
cognitive decline as well as an increased incidence of skin cancer in patients (De Strooper, 
2014).   
 
Another avenue for direct inhibition of the amyloidogenic pathway is BACE1 inhibition. 
Cleavage of APP by BACE1 has not only been demonstrated to be the rate-limiting step of Aβ 
generation (Stockley and O'Neill, 2007) but, in a study on BACE1-knockout mice (Luo et al., 
2003) a lack of BACE1 did indeed reduce the amount of Aβ present in the adult mice. Concern 
for the use of  BACE1 inhibition as a method of AD treatment is directed  towards the lack of 
knowledge surrounding its functions outside of APP cleavage as BACE1 knockout mice, 
although not presenting with AD, do present some abnormal phenotypes such as seizures 
resulting from an over excitation of neurons as well as hypomyelination (Hu et al., 2006). 
Further, with the recent failure of the BACE1 inhibitors, Verubecestat and Lanabecestat  
(Hawkes, 2017; Burki, 2018), it has become apparent that these BACE1 inhibitors resulted in 
an increase in the rate of cognitive decline in patients, this was not seen in the phase 2 trials of 
Elenbecestat, another BACE1 inhibitor produced by Biogen, Eisai Co., Ltd., however. BACE1 
has been implicated in several brain functions such as neuronal plasticity, synapse formation 
and myelination which could explain the adverse effects of BACE1 inhibition. Several studies 
have tried to determine possible BACE1 substrates in an effort to determine what adverse 
effects could result from its inhibition (Hemming et al., 2009; Kuhn et al., 2012) . These studies 
suggest that BACE1 might play a role in neurogenesis (Modarresi et al., 2011). Further efforts 
to generate AD drugs have followed the exploration of several other modes of treatment, 
including the use of antibodies against either amyloid-β or tau protein (Doody et al., 2014; 
Bohrman et al., 2012; Cummings et al., 2014; Sevigny et al., 2016). The goal of these 




The first protein targeted as a potentially important component of AD pathology was the 
enzyme acetylcholinesterase (AchE), with three of the four currently marketed AD drugs being 
AchE inhibitors (Tabet, 2006). Inhibition of AchE reduces the rate at which acetylcholine is 
degraded, thereby maintaining the levels of the neurotransmitter in the brain, slowing cognitive 
decline. The fourth drug, and the only FDA approved treatment method that does not target 
acetylcholinesterase is an NMDAR inhibitor in the glutamatergic system.  
1.3 Targeting of Alzheimer’s disease pathways over proteins, as a potential avenue for 
treatment  
1.3.1. The interconnected pathways resulting in Alzheimer’s disease 
It has become abundantly clear, due in no small part to the failure of several drug candidates 
aimed at inhibiting the amyloid pathway, that targeting the amyloid cascade alone is insufficient 
in curbing the cognitive decline associated with AD (Hawkes, 2017). This is unsurprising given 
the complex and interconnected nature of the many facets of the disease. The failures of drug 
candidates targeting the amyloid pathway do not necessarily rule out Aβ as a major player 
however, instead these failures suggest an emphasis would be better placed on the points of 
intersection between the various involved pathways rather than simply targeting one pathology 
at a time. This is further evidenced by recent genome-wide association studies that have shown 
risk factor genes for AD that encode for proteins involved in lipid homeostasis, regulation of 
microglial activation as well as several genes in mitochondrial DNA (Bin et al., 2019, dos 
Santos et al., 2017, Kunkle et al., 2019). This inflammatory response in the brain is mediated 
by two cell types, astrocytes and microglia. When the microglia become activated into either 
M1 or M2 forms, typically through injury, M1 microglia produce pro-inflammatory cytokines 
while M2 microglia have an anti-inflammatory response (Yang et al., 2019). It has been 
demonstrated in mice that activated microglia and astrocytes further promote Aβ plaque 
formation (Guo et al., 2002) which can compound the initial inflammatory signal as Aβ induces 
further activation of the complement system, which further facilitates microglial activity, 
resulting in a colocalization of microglia with amyloid plaques (Matsuo et al., 2017). The 
aggregation of Aβ can further enhance an inflammatory response through enhancing the 
Nuclear Factor κ-light-chain-enhancer of activated B cells (NF-κβ) and Mitogen-activated 
protein kinase (MAPK) pathways which have both been shown to stimulate expression of pro-
inflammatory genes (Lim et al., 2013, He et al., 2020, Kim et al., 2018). The NF-κβ pathway 
further increasing BACE1 gene expression as well as BACE1 activity resulting in further Aβ 
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production. This has further ramifications as Aβ results in increased activity of the nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase complex found within microglia which, 
combined with the M1 microglia’s natural production of inducible nitric oxide synthase (iNOS), 
results in an increase in oxidative stress (Neniskyte et al., 2016).  
 
ApoE has also been shown to interact with both Aβ and tau, with this interaction being 
facilitated by lipid rafts. Further, it has been seen to influence the removal of Aβ from the brain. 
While ApoE is the major AD-related protein involved in lipid homeostasis, a non-protein 
molecule of particular interest to AD is cholesterol. Cholesterol itself is present in myelin as 
well as neuronal and glial membranes and plays a major role in the formation of lipid rafts, lipid 
rafts being where ApoE interacts directly with Aβ and tau (Rushworth et al., 2013). Decreased 
levels of cholesterol have been implicated in an uptick of Aβ production however elevated 
levels have also been implicated in early stage AD indicating that any divergence from 
cholesterol homeostasis can increase AD susceptibility (Merched et al., 2000, Ghribi et al., 
2006). Lipid rafts are also where Aβ can form complexes with gangliosides (Grimm et al., 
2012). These complexes have been seen to disrupt cell membrane stability and permeability, 
which has been seen to confer Aβ cytotoxicity and is also regulated by cholesterol levels. 
Cholesterol also induces colocalization of BACE1 and APP at lipid rafts leading to increased 
Aβ production (Vetrivel et al., 2009b). Increased APP cleavage leads to increased extracellular 
cholesterol levels resulting in further disruption of homeostasis. Oligomeric tau is also 
detrimental to the brain due to both its ability to disrupt membranes resulting in toxicity as well 
as disrupt autophagy of Aβ aggregates (Ait-Bouziad et al., 2017). Further ways in which tau 
processing proteins are intertwined with Aβ is through the tau truncating protein caspase 3, 
which catalyses tau truncation at its C-terminus and exhibits higher activity in the presence of 
Aβ (Cotman et al., 2005). 
1.3.2. Potential viability of a multitarget approach for treating Alzheimer’s disease  
Given the numerous proteins and pathways directly implicated in Alzheimer’s disease it has 
become abundantly clear that no single protein is solely responsible for the onset of AD. As a 
result, once symptoms begin to manifest in patients, treatments that target single proteins are 
unlikely to have permanent affects, even evidenced by the recent success of Biogen’s 
aducanumab anti-Aβ antibody treatment (Biogen, 2019). This treatment indicates that continual 
removal of Aβ plaques may be possible and effective, however given that aducanumab 
treatment requires repeated intravenous administration, it clearly indicates that the underlying 
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disruption in brain homeostasis remains. This is likely due to the interconnectedness of all the 
implicated pathways in AD. As a treatment corrects one proteins levels, Aβ levels in the case 
of aducanumab, the remaining disrupted pathways restore the levels over time. Targeting of 
multiple pathways in tandem may thus increase the time it takes for these pathways to return to 
the disrupted levels. This lends value to the exploration of further treatments targeting BACE1 
despite the recent clinical failures. 
1.4 The BACE1 enzyme as a target 
1.4.1. BACE1 localization and function 
The BACE1 protein is present in the majority of tissues in the body however it is expressed to 
a larger extent in the brain, where it is predominantly expressed in neurons. It has however been 
reported that although astrocytes do express BACE1 to a lower extent, they are capable of 
expressing enzymatically active BACE1 (Vassar et al., 1999; Robner et al., 2004). It is a 
transmembrane enzyme with a pH optimum of 4.5 resulting in it being most active inside the 
lumen of endosomes and the Golgi apparatus where it is colocalized with APP prior to APP 
cleavage (Skovronsky et al., 2000). It is also present on the cell membrane in lower 
concentrations as well as in synaptic vesicles (Lundgren et al., 2015). It is active as a monomer 
however dimerization is necessary for maximal activity (Schmechel et al., 2004). Although it 
is named after its ability to cleave APP, it has been reported to also act on neuregulin-1 through 
which it facilitates maturation and maintenance of muscle spindles (Cheret et al., 2013). Other 
BACE1 substrates include the seizure protein 6 and seizure 6 like protein, which have been 
linked to synapse dysfunction (Pigoni et al., 2016). BACE1 has also been implicated in the 
regulation of astrocyte and neuron formation through cleavage of the Jagged1 signalling protein 
(Hu et al., 2013). It also plays a role in myelination of neurons as well as neuroplasticity as 
mentioned prior. 
1.4.2. BACE1 domain structure and notable features 
The BACE1 enzyme is an aspartic protease synthesized as a 501 amino acid peptide with five 
domains, which include the C-terminal cytosolic domain, the transmembrane domain and the 
catalytic domain. There is also a pro peptide region and an N-terminal signal peptide, both of 
which are cleaved off resulting in the fully active enzyme (Dislich and Lichtenthaler, 2012). 
The transmembrane and cytosolic domains play a role in BACE1 regulation as both the 
transmembrane and cytosolic domain assist in dimerization whilst the cytosolic domain is 
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required for trafficking of the protein (Yan et al., 2001; Schmechel et al., 2004). The BACE1 
protein has three disulphide bonds, with each being required for activity as they maintain the 
correct conformation of the active site cleft. It is also the subject of extensive post-translational 
modifications. The protein is glycosylated four times, with these glycosylations not being 
integral to activity, however they are required for maximal activity (Huse et al., 2000). It also 
contains four palmitoylation sites as well as seven acetylation sites. Palmitoylation occurs on 
the cytosolic domain and assists in the formation of homodimers (Vetrivel et al., 2009a). 
Acetylation is not permanent and only occurs in immature BACE1 forms to facilitate transport 
(Costantini et al., 2007). 
1.4.3. The catalytic domain 
The catalytic domain of the enzyme has two catalytically active aspartate residues, 
characteristic of aspartic proteases and consists of an N-terminal and C-terminal lobe. One of 
the major features of the catalytic domain is the presence of an antiparallel hairpin loop 
commonly called a “flap”, which is a common feature of aspartic proteases. This flap is integral 
for BACE1 inhibitor design as it plays a major role in allowing substrates access to the active 
site cleft. It is also implicated in ensuring the correct conformation of substrates in the binding 
site as well as the removal of the products of hydrolysis from the active site cleft (Xu et al., 
2012). The large binding site of BACE1 in some cases, can accommodate up to 11 amino acids 
(Turner et al., 2001). The three-dimensional (3D) BACE1 structure is represented in Figure 1.2. 
1.4.4. Catalytic site specificity 
The most commonly used assays BACE1 activity assays utilize the so-called “Swedish 
mutation" APP (Mancini et al., 2011). This mutant is the result of a double mutation of the 
wild-type APP which is correlated with an increased susceptibility to AD due to the mutation 
increasing the affinity of the substrate for BACE1 cleavage (Haass et al., 1995). This substrate 
coupled with various combinations of fluorophores and quenchers is used for its high sensitivity 
for BACE1 proteolytic activity as well as its applicability to the multi-well format. The 
sensitivity of these assays is a major concern for BACE1 assays however, as the BACE1 
catalytic sites affinity against the β-site of APP is low, even with the Swedish mutation (Turner 
et al., 2001). This has led to the development of optimized substrates for the BACE1 catalytic 
site, with the optimal amino acid cleavage site containing a leucine at P1, valine at P3 and 
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alanine or valine at P2’. BACE1 diplays higher affinity for hydrophobic residues at P1 and P3 
(Tomasselli et al., 2003).  
 
 
Figure 1.2: The 3D BACE1 catalytic domain. The three-dimensional ribbon representation of the BACE1 
catalytic site (Protein DataBank (PDB) ID 5HU1, visualized using the Schrodinger Biologics suite (2018-2) with 
the tyrosine 71 residue (Encapsulated in purple) and catalytic aspartate dyad represented in grey (Encapsulated in 
yellow). N-terminal lobe represented in green, C-terminal lobe represented in red. 
1.4.5. BACE1 proteolytic mechanism 
The BACE1 protein functions similarly to other aspartyl proteases, utilizing the aspartate dyad 
in conjunction with a preserved water molecule in its active site to bring about peptide bond 
cleavage. Initially, the Asp32 residue is protonated while the Asp228 residue is not. As seen in 
panel A of Figure1.3 the Asp32 residue functions as a proton donor, passing on a hydrogen 
atom to the peptide bond’s carbonyl oxygen. Simultaneously, the unprotonated Asp228 takes 
on a proton from the active site water molecule, creating a nucleophilic hydroxyl group which 
then acts on the peptide bond of the substrate, forming a geminal diol intermediate. This is the 
rate-limiting step of the reaction. In panel B, cleavage of the peptide bond occurs when Asp32 
sequesters a proton from the intermediate, while Asp228 donates a proton to the nitrogen atom 
of the peptide bond. Finally in panel C, the N-terminus dissociates from the Asp32 residue 






Figure 1.3: The proposed three-step cleavage of a peptide bond by the aspartate dyad of BACE1. The 
catalytic aspartates are represented on the left, with the substrate peptide bond on the right. The catalytic water 
molecule is also displayed. Arrows indicate atom interaction. Solid lines indicate covalent bonds, dashed lines 
indicate hydrogen bonds. Taken from Paul et al., 2016. 
1.4.6. Concerns regarding BACE1 as a target for Alzheimer’s disease treatment 
A concern for the use of BACE1 inhibition as a form of AD treatment stems from the BACE1 
homolog, β-site APP cleaving enzyme-2 (BACE2). The BACE2 amino acid sequence possesses 
64% similarity, with 51% identity, to that of BACE1. This similarity in structure is highlighted 
in Figure 1.4 in which the structures of BACE1 and BACE2 are superimposed on each other. 
BACE2 is present in most tissues of the human body, much like BACE1, and is expressed 
highest in the pancreas. It is not highly expressed in the brain however, though BACE2 activity 
has been reported in the brain. Studies have been carried out on BACE1 and BACE2 knockout 
mice where BACE2 knockout mice displayed a healthy phenotype compared to the complicated 
phenotypes of BACE1 knockout mice summarized in section 1.2.4. Mice incapable of 
expressing either BACE1 or BACE2 presented higher lethality, resulting in a survival rate of 
40%, whereas mice incapable of expressing either BACE1 or BACE2 exhibited no such 
lethality (Dominguez et al., 2005). This is of concern as any compound that can inhibit both 
BACE1 and BACE2 due to the high degrees of similarity may result in detrimental side-effects. 
With regards to its ability to cleave APP, BACE2 can cleave at the APP β-cleavage site, 






Figure 1.4: BACE2 structure superimposed onto BACE1. The BACE1 (5HU1) and BACE2 (2EWY) structures 
were superimposed using the Schrodinger Biologics suite (2018-2) aligning their respective catalytic aspartates. 
BACE1 is coloured in blue while BACE2 is represented in green. The catalytic aspartate dyad is represented in 
grey. 
1.4.7. Generation of BACE1 protein for study 
A protocol for reliable production of soluble, active BACE1 was published in 2003 (Sardana et 
al., 2003). This bacterial expression however resulted in 3.5 mg/L of culture due to aggregation 
during affinity purification. Large scale, high yield expression of BACE1 for study has still 
proven to be difficult due to the protein’s expression in inclusion bodies as well as its tendency 
to aggregate. Expression in mammalian cells, such as human embryonic kidney (HEK)-293 and 
Chinese hamster ovary (CHO)-K1 cell lines has also been carried out (Emmons et al., 2008), 
however since the protein has a total of four glycosylation sites, BACE1 generated in 
mammalian cell lines is difficult to use for crystallographic studies as these glycosylations often 
lead to low resolution crystals (Chang et al., 2007). Further, mammalian cell expression is 
associated with low protein yields, relative to bacterial expression with BACE1 expression in 
HEK-293 cells yielding 1.5 mg/L and expression in CHO-K1 cells yielding 0.75 mg/L 
(Emmons et al., 2008). Bacterial expression has drawbacks however, as the protein has three 
disulphide bonds which are required for activity, necessitating further steps to ensure the protein 
is correctly folded (Tomasselli et al., 2008). Furthermore the glycosylations have been 
demonstrated to be necessary for maximum proteolytic activity (Sathya et al., 2012). The yields 
in Escherichia coli (E. coli) are however six times higher than those found in mammalian cells 
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with the protocol yielding the highest amount of BACE1 producing 7 mg/L of recombinant 
protein while also producing high resolution crystal structures (Tomasselli et al., 2008). This 
expression however requires a lengthy three-day incubation to allow for refolding of the 
recombinant protein. 
 
1.5 Drug Discovery 
The discovery of drugs is a process that spans around 15 years from initial target identification, 
as seen in Figure 1.5. The major phases of the drug discovery pipeline include target 
identification, development and application of screening assays, preclinical assessments of 
safety, usually carried out in animal models, clinical trials, ending finally in approval for sale 
(Roses, 2006). After the identification of a target and confirmation of its drugability, the 
screening process can be carried out in two ways, random high-throughput screening or the 
rational drug design approach. The random approach relies on the screening of large numbers 
of drug-like compounds against the protein target whereas the drug design approach may be 
further divided into structure-based and ligand-based. Structure-based techniques utilize 
structures of the target protein derived from nuclear magnetic resonance spectroscopy (NMR), 
crystallography or homology modelling to design ligands specifically for the active site. These 
drug design techniques include de novo drug design as well as fragment-based approaches 
(Murray and Rees, 2009; Congreve et al., 2007). Ligand-based methods utilize pharmacophore 
models which compiles common features and functional groups found in known ligands of the 
target protein and then allow screening for compounds that possess similar structures. Another 
ligand-based approach utilizes the technique quantitative structure activity relationship (QSAR) 
as a way of designing and optimizing known ligands (Kubinyi, 1997).  
 
 
Figure 1.5: The drug discovery pipeline from initial target identification to clinical trials and FDA approval. 
The initial drug development stages including target identification, compound screening and hit identification are 
indicated in light blue, clincal trials indicated in green with the end result of FDA approval indicated in dark blue. 
Taken from Roses, 2006. 
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1.5.1 Differential Scanning Fluorimetry 
Differential scanning fluorimetry (DSF) is a ligand binding assay that uses the random-based 
approach to screen for binding molecules. It takes advantage of the process of denaturation of 
proteins when exposed to high temperatures as well as the ability of bound ligands to increase 
protein stability. This is carried out through the use of a fluorescent dye capable of binding to 
hydrophobic protein residues. Over the course of a DSF experiment, the temperature of the test 
solution is gradually increased. As this occurs, the protein in question begins to denature 
exposing its hydrophobic residues, allowing the fluorescent dye to bind. This binding is 
detected by an increase in fluorescence until a temperature is reached where the protein begins 
to dissociate from the dye. The relationship between temperature and fluorescence is then used 
to determine the proteins melting temperature (Tm) as shown in Figure 1.6. When in the 
presence of a ligand, this Tm increases as the ligand enhances the stability of the bound protein. 
This difference is referred to as a thermal shift (Niesen et al., 2007). DSF is highly amenable 
to automation and, through the use of multi-well plates allows for high-throughput screening 
(Menzen and Friess, 2012). It does allow for the elucidation of the proteins standard Gibbs 
energy of unfolding (ΔuG˚) which can be used as an inference of the proteins thermal stability 
(Wright et al., 2017). The DSF assay also allows the elucidation of the class of unfolding, 
whether single-state or two-state unfolding.  
 
The DSF assay does have drawbacks however as it only detects molecules capable of binding 
to the target protein, this does not always correlate to inhibition however. This drawback may 
potentially be why the use of the DSF assay to screen for unknown BACE1 inhibitors has not 
been reported, with the only reported use of DSF being carried out on BACE1 being a study 
assessing the viability of the DSF assay utilizing known BACE1 binding compounds (Lo et al., 
2004). With the recent increase in the use of proteolysis targeting chimers (PROTACs) as a 
means to induce protein degradation however, the downside of being unable to detect inhibition 
is irrelevant. Furthermore, given the failure of the Verubecestat in phase 3 trials despite the 
compounds potent BACE1 inhibitory ability, new means of targeting and reducing BACE1 







The use of the CETSA for the study of BACE1 has not been reported however and thus could 
be a novel means of detecting intracellular BACE1 binding compounds. Of further interest with 
regards to the screening of BACE1 binding compounds is that potentially insight into the 
intracellular binding of both the BACE1 monomer and dimer could be obtained given BACE1 
has been reported to present natively as a homodimer (Westmeyer et al., 2004). It is not possible 
in assays such as DSF and FRET to easily separate BACE1 dimers from monomers, however 
since the CETSA analysis is carried outviawestern blot, the dimer is separated from the 
monomer naturally through electrophoresis. This ability to separate dimers could potentially 
allow for the screening of compounds that target the BACE1 dimer specifically. 
1.5.3 Molecular Docking 
Molecular docking is a structure-based drug design technique for in silico screening. It is 
commonly used for screening for BACE1 ligands due to the ubiquity of BACE1 crystal 
structures available on the Protein DataBank (PDB). Compounds are screened using software 
that predicts binding affinity of the ligand in the active site of the protein in question. This 
affinity is assigned a score which can then be compared to the scores of all other compounds 
screened in this way. Initial models of BACE1 are typically generated using a 3D structure of 
BACE1 co-crystallized with a ligand, imported from the PDB. The position of the ligand is then 
used to define a receptor grid. Compounds that are rendered in 3D can then be screened against 
this receptor grid. This method is effective for initial hit identification as it allows for rapid and 
inexpensive screening of large compound libraries. A commonly used molecular docking 
program is the Glide (Grid-based Ligand Docking with Energetics) program. Initially, a 
compound is separated into several conformations, generated through rotations around the 
compounds rotatable bonds (Friesner et al., 2004). These conformations are then fit into the 
receptor grid active site, with their positions being assessed with regards to location inside the 
receptor grid. Conformations that fit correctly into the receptor grid, then have their energies 
minimized using Optimized Potential for Liquid Simulations-All Atoms (OPLS-AA) 
forcefields. The lowest energy conformations are then subjected to Monte-Carlo simulations to 
determine the final, lowest energy conformations in the receptor grid. Lastly interactions 
between the receptor and the ligand are assessed and assigned scores, referred to as Glide 
scores, where lower the Glide scores indicate tighter binding of the ligand to the receptor. 
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Ligand conformations will then typically be exposed to molecular dynamics simulations to 
validate and better define the bound ligand conformation (Kumar et al., 2017). 
1.5.4 The zebrafish embryo toxicity test 
The zebrafish, Danio rerio, is a bony fish native to regions of India and its surrounding 
countries. Zebrafish were first used in the 1970s as models to not only measure toxicity, but 
studies were also carried out on their neuronal structure as well as on their spawning cycle and 
clutch sizes (Eaton and Farley, 1975, Eaton and Farley, 1974, Thomas, 1975). These studies 
resulted in the genome of the zebrafish ultimately being fully sequenced in 2001 by the 
Wellcome Trust Sanger institute (Howe et al., 2013). The use of zebrafish as not only a toxicity 
model but a model organism has increased substantially since then due to the several benefits 
over other, more established models (Teame et al., 2019). The major benefits include the 
frequent production of large numbers of embryos that are largely transparent throughout the 
developmental stages. These benefits make zebrafish embryo toxicity test (ZFET) amenable to 
high throughput screening due to the large and frequent number of embryos, with toxicity 
endpoints being assessable in real time due to their transparency. Furthermore, studies have 
demonstrated that zebrafish have orthologues for around 70% of all genes found in humans, 
contributing to their viability as a model organism for human diseases. 
 
The ZFET was established as a means to quantify toxicity using zebrafish embryos. This assay 
was adopted by the Organisation for Economic Co-operation and Development (OECD) with 
strict guidelines being created for its use, to ensure reliability (OECD, 2013). These guidelines 
layout the specific endpoints to take note of when carrying out the ZFET, stipulating that the 
determination of lethality be carried out as a function of four observations. The first of these 
observations being the coagulation of an embryo, resulting in a non-viable embryo incapable 
of developing further. Secondly, the lack of somite formation along the tail of the fish indicates 
the presence of toxicity, typically resulting in deformities in the tail of the fish as well as 
observable spinal curvature. The third toxicity endpoint is the non-detachment of the tail from 
the main body of the embryo which is observable after 24 hours of development and finally the 
lack of any heartbeat from 48 hours onward confirms lethality. All of these endpoints are easily 





Teratogenicity is another property that is measurable using a modification of the ZFET, making 
use of the transparent nature of the embryos even after being fully developed. Zebrafish grown 
over the course of five days are typically possess all of the structures present in adult zebrafish 
allowing for the assessment of how correctly these structures are formed. This scoring system, 
first established by Panzica-Kelly and colleagues provided a reliable means with which to 
quantify levels of deformity (Panzica-Kelly et al., 2010). This method relies on the assessment 
of nine observable structures in the five-day old embryo, with lower scores denoting a greater 
degree of malformation, as displayed in Figure 1.7. This method allowed for the calculation of 
a teratogenicity index (TI) through the determination of the no-observed-adverse-effects level, 
which is denoted as the concentration at which no change in the morphological score was 
observed. This method has since been updated, rather than relying on the determination of the 
no-observed-adverse-effects level, more easily calculated values are now used. These values 
being the concentration at which lethality of a compound is 50% (LC50) and the concentration 
at which the morphology score is 50% of the maximum score (EC50) (Alafiatayo et al., 2019). 
The ratio between the LC50 and the EC50 being the TI, with teratogenicity being denoted if the 
TI is greater than 1. This allows for the zebrafish to function as a robust means to measure 




Figure 1.7: The profile of a five-day old zebrafish, denoting each of the major structures. The upper jaw 
denoted by UJ, The forebrain denoted by FB, MB denotes the midbrain, HB, the hindbrain, OC, the otic capsule, 
E, the eye, SB, the swim bladder, NC, the notochord, S, the somites, T, the tail, LJ, the lower jaw, H, the heart, L, 





1.6 Hypothesis, Aims and Objectives 
 
The cellular thermal shift assay is a powerful tool for detecting intracellular target engagement 
of protein ligands, however it has yet to be utilized in the search for BACE1 binding ligands. It 
was hypothesized that the CETSA could be used to aid in the search for BACE1 ligands. The 
aim of this study was to assess the thermostability of BACE1 and determine the viability of 
using thermostability as a means to detect BACE1-ligand binding in light of its reportedly high 
thermostability. This was carried out through the following objectives: 
1. Recombinantly expressed BACE1 yields, greater than those found in literature, were 
determined to be possible. 
2. The value of utilizing thermostability of BACE1, for compound screening, was assessed 
and confirmed. 
3. The comparability between in vitro and in silico BACE1 ligand screening was explored. 
4. Intracellular binding capabilities of BACE1 ligands, determined in Objective 2, were 
evaluated. 
5. The use of the compound from Objective 4, that was detected to bind BACE1 
intracellularly, for use as a precursor to clinically relevant BACE1 ligands was 
examined.  






CHAPTER 2: MATERIALS AND METHODS 
2.1 Plasmid preparation and Escherichia coli transformation 
2.1.1 rBACE1-pGEX4T-1 plasmid synthesis and the transformation of E. coli 
The gene sequence for human BACE1 was obtained from GenBank (GeneID: 23621). The 
amino acid sequence for human BACE1 was obtained from UniProt (BACE1_HUMAN). The 
peptide sequence was assessed with regards to hydrophobicity using the online protein analysis 
tool, ProtScale (Swiss Institute of Bioinformatics, Switzerland), as well as analysed for 
cleavage sites from common proteases using PeptideCutter (Swiss Institute of Bioinformatics, 
Switzerland). The nucleotide sequence was analysed for restriction digestion sites using the 
online tool NEBCutter (New England Biolabs, USA). The sequence coding for the truncated 
BACE143-454 gene was then synthesised into the pGEX4T-1 plasmid by GenScript (USA). This 
construct is henceforth referred to as the BACE143-454–glutathione-S-transferase (GST) 
plasmid. This gene was subjected to codon optimization to ensure maximal expression in E. 
coli cells (Burgess-Brown et al., 2008). E. coli BL21 (DE3) cells were transformed using 
calcium chloride transformation as per Dagert and Ehrlich (1979). Briefly, a glycerol stock of 
untransformed E. coli BL21 (DE3), purchased from New England Biolabs (USA), was plated 
onto 2xYT agar (16 mg/ml tryptone, 10 mg/ml yeast extract, 5 mg/ml NaCl, 100 µg/ml 
ampicillin, 1.5% (w/v) bacteriological agar, all purchased from MilliporeSigma, USA) and 
incubated overnight at 37°C. From this a single colony was selected and grown in 2xYT broth 
(16 mg/ml tryptone, 10 mg/ml yeast extract, 5 mg/ml NaCl, 100 µg/ml ampicillin) for 16 h at 
37°C, shaking at 200 revolutions per min (RPM). This culture was then diluted 1:100 with fresh 
2xYT broth and grown in the same conditions until an optical density (OD), at a wavelength of 
600 nm, of 0.3 - 0.4 was reached. The culture was then transferred to ice-cold centrifuge tubes 
and centrifuged at 4000 xg for 10 mins at 4°C. The pellet was subsequently resuspended in ice-
cold sterile CaCl2 solution (60 mM CaCl2, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer, pH 7.0, all purchased from MilliporeSigma, 
USA). The resuspended pellet was then centrifuged under the same conditions as before and 
the pellet resuspended in a volume of CaCl2 solution equal to 1 / 50
th the final culture volume.  
 
The resulting cell mixture was then incubated with 1 / 20th the volume of BACE143-454 –GST 
plasmid for 30 mins on ice. These cells were then heat-shocked at 42°C for 90 s and further 
incubated on ice for two mins. The cell solution was then added 1:4 to Super Optimal broth 
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with Catabolite repression (SOC) media (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose, all purchased from MilliporeSigma, 
USA) and incubated at 37°C for 1 hour with gentle agitation. The resulting mixture was then 
plated onto a pre-warmed 2xYT plate and incubated for 16 h, again at 37°C. This plate was then 
used to generate glycerol stocks of the transformed E. coli cells. Herein, ten 2 ml, 2xYT aliquots 
containing ampicillin (MillporeSigma, USA) were inoculated with single colonies, with these 
cultures being incubated at 37°C for 16 h with 200 RPM shaking. After this sterile, glycerol 
was added to a final concentration of 7.5%. These glycerol stocks were then stored at -70°C. 
2.1.2 Plasmid Isolation and restriction digestion 
The glycerol stock containing the E. coli BL21 (DE3) cell line (New England Biolabs, USA) 
were plated onto 2xYT agar and incubated overnight at 37°C. A single colony was then grown 
in 2xYT broth overnight as before. From this overnight culture, plasmid DNA was isolated 
using the GeneJet plasmid DNA isolation kit (Thermo Fisher Scientific, USA) as per the 
instructions provided by the manufacturer. Restriction digestion was carried out on the isolated 
DNA using EcoR1 (1U) and BamH1 (2U) in 2 x “Tango” buffer (Thermo Fisher Scientific, 
USA) overnight at room temperature.  
2.1.3 Agarose gel electrophoresis 
The samples that were exposed to restriction digestion, were analysed on a 1% (w/v) agarose 
gel alongside the undigested plasmid, as well as 5 µl of O’GeneRuler 1 kb DNA ladder (Thermo 
Fisher Scientific, USA). This agarose gel was made by dissolving agarose to a final 
concentration of 1% (w/v) in 1 x Tris (hydroxymethyl) aminomethane (Tris)-acetate-ethylene 
diamine tetra-acetic acid (EDTA) buffer (TAE buffer) (40 mM Tris-HCl, 20 mM glacial acetic 
acid, 1 mM EDTA) containing 0.5 µg/ml ethidium bromide (Invitrogen, USA). Visualization 
was carried out using a GeneSys G-box gel visualization system (Syngene, India) with 
ultraviolet light. 
2.1.4 Plasmid sequencing and purity analysis  
To assess the final concentration and purity of the isolated plasmid, A280 and A260 values were 
measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). This 




2.2 Expression of rBACE1 in Escherichia coli 
2.2.1 Determining the solubility of rBACE1-GST 
2xYT broth with ampicillin was inoculated with a single colony of transformed E. coli. This 
was then grown overnight at 37°C while shaking at 200 RPM. This overnight culture was then 
used to inoculate two separate 2xYT broths, at a 1 in 100 dilution. The resulting cultures were 
then incubated at 37°C, 200 RPM until an OD600 of 0.4 was reached. After this, 1 mM IPTG 
(Thermo Fisher Scientific, USA) was added and the resulting induced culture incubated at 
37°C, 200 RPM for 4 h. After induction was complete, the cells were harvested through 
centrifugation at 4000 xg for 10 mins at 4°C. 
 
The supernatants were discarded and the pellet resuspended in phosphate buffered saline (PBS) 
pH 7.4 (2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4, 150 mM NaCl in 500 ml), equal in 
volume to 10% of the original culture volume. The resuspended sample was then sonicated 5 
times for one min with one min intervals on ice and subsequently centrifuged at 10 000 xg for 
20 mins at 4°C. The supernatant was stored at 4°C as the PBS soluble sample. The pellet was 
then resuspended in resolubilization buffer (50 mM Tris-HCl, 8 M urea, 10 mM 2-
mercaptoethanol, pH 9.0, all purchased from MilliporeSigma, USA) equal in volume to 5% of 
the original culture volume.  
2.2.2 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis and Western Blot 
Analyses  
After expression, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis was carried out on all samples under non-reducing conditions in accordance with 
Laemmli (1970). Briefly, a 1 mm thick, polyacrylamide gel, comprised of a running gel and 
stacking gel containing 12.5% and 4% acrylamide respectively, was loaded with a molecular 
weight marker alongside protein samples treated with non-reducing treatment buffer (125 mM 
Tris-HCl, 4% SDS, 20% glycerol, with bromophenol blue). Three molecular weight markers 
were used throughout the study with the three being: the SeeBlue Plus2 Pre-stained Protein 
Standard molecular weight marker, Spectra™ Multicolor Broad Range Protein Ladder 
molecular weight marker and Pageruler Plus prestained protein standard, purchased from 
Thermo Fisher Scientific (USA). Each gel was electrophoresed at 20 mA in tank buffer (250 
mM Tris-HCl, 192 mM glycine, 0.1% (w/v) SDS) to completion. Gels were then either stained 
or analysedviaa western blot. Gels were stained using Coomassie blue staining solution 
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(0.125% (w/v) Coomassie brilliant blue R-250 (MilliporeSigma, USA), 50% (v/v) methanol 
(RadChem, USA), 10% (v/v) glacial acetic acid (RadChem, USA)). Molecular weight values 
for bands corresponding to unknown proteins were determined using molecular weight 
markers. The distance travelled by each marker was plotted against each bands corresponding 
log(molecular weight). A line of best fit was derived and used to calculate the molecular weight 
of any bands representing proteins of unknown molecular weight. 
 
Western blotting was carried out by first transferring proteins from a polyacrylamide gel to a 
nitrocellulose (MilliporeSigma, USA) or a polyvinylidene difluoride (PVDF) membrane (Pall 
Corporation, USA), with the PVDF membrane being pre-wet in methanol prior to transfer. 
Transfers were carried out using a Bio-Rad overnight transfer system (Bio-Rad, USA). This 
was carried out overnight in blotting buffer (25 mM Tris-HCl, 190 mM glycine, 20% (v/v) 
methanol, 0.1% (m/v) SDS). After protein transfer, the membrane was blocked for an hour 
using 5% (w/v) low-fat dry milk powder dissolved in Tris buffered saline (TBS; 20 mM Tris-
HCl, 200 mM NaCl, pH 7.4) containing 0.1% Tween-20. After blocking, the blot was washed 
three times with TBS-Tween after which, primary antibodies in TBS-Tween, containing 0.5% 
Bovine serum albumin fraction V (BSA, Biowest, France) were added. The blot was then 
incubated at room temperature for three h with gentle mixing. Both the rabbit anti-BACE1 
primary IgG antibodies (MillporeSigma, USA) and chicken anti-GST IgY antibodies (kindly 
provided by Professor Theresa Coetzer) were used at a concentration of 2 µg/ml. The blot was 
again washed with TBS-Tween three times with secondary antibody then being added. The goat 
anti-chicken (Advansta, USA), as well as the goat anti-rabbit IgG antibodies (MilliporeSigma, 
USA) were used at dilutions of 1:10 000, both of which were conjugated to horse radish 
peroxidase (HRPO). Secondary antibody incubation was carried out for one hour at room 
temperature, again with gentle mixing. The blot was then washed and the protein bands 
visualized with an enhanced chemiluminescent (ECL, Bio-Rad, USA) substrate kit and imaged 
using a Syngene Chemi XR5 G-box with GeneSys gel visualization software (Syngene, India). 
 
2.2.3 Optimization of expression conditions 
After confirmation of the presence of rBACE1-GST in the cell lysate, the expression conditions 
were optimized with regards to type of media, IPTG concentration, induction time and 
induction temperature. The types of media compared were 2xYT media and lysogeny broth 
(LB) (8 mg/ml tryptone, 5 mg/ml yeast extract, 5 mg/ml NaCl, 100 µg/ml ampicillin). The two 
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IPTG concentrations 0.5 and 1 mM, two different induction times, namely four h and overnight 
induction as well as the induction temperatures 16°C and 37°C were also compared.  
2.2.4 Use of anti-aggregation to generate soluble rBACE1-GST 
Several conditions were tested including 1% polyethylene glycol (PEG) 6 000, 10% glycerol, 
1% Triton X-100, 200 mM L-Arginine and 200 mM sucrose. These were added to the cell pellet 
after resuspension in PBS. This was followed by sonication and centrifugation as before, with 
the soluble and insoluble fractions being compared on an SDS-PAGE gel. 
2.2.5 Resolubilization and refolding of rBACE1-GST 
Initially a refolding strategy was attempted using a ratio of oxidized and reduced glutathione. 
Briefly, after expression, the soluble and insoluble fractions of the cell lysate were separated 
and the insoluble fraction resuspended in resolubilization buffer equal in volume to 5% of the 
original culture volume. This was then diluted 1 in 20 in refolding buffer (20 mM Tris-HCl, 0.5 
mM oxidized glutathione, 2.25 mM reduced glutathione, pH 9.0) with the sample then being 
incubated at 4°C for four h after which it was titrated to pH 8.0. Further, this was incubated at 
4°C for 48 h, titrated to pH 6.8 and further incubated for another 48 h at 4°C as per. The resulting 
solution was then dialyzed against PEG 20 000 in regenerated cellulose, molecular weight cut-
off (MWCO) 10 000, Snakeskin™ dialysis tubing (Thermo Fisher Scientific, USA). 
 
A further technique involving the incubation of the insoluble protein fraction in a 10% N-lauryl 
sarcosine (sarkosyl) solution for 24 h was also tested. In this, the insoluble pellet was dissolved 
in PBS containing 10% sarkosyl and incubated at 4°C for 24 h, after which the solution was 
diluted 1 in 5 reducing the sarkosyl concentration before column purification, further, 4% Triton 
X-100 was then added. 
2.2.6 Glutathione-agarose column purification 
A glutathione-agarose gravity column (MilliporeSigma, USA), 1 ml in volume was swollen and 
equilibrated to the relevant buffer as per instructions provided by the manufacturer (Catalogue 
number: G4510). After this, the sample containing the GST fusion protein was incubated in the 
resin for one hour with constant mixing. The column was then left to settle and subsequently 
washed with PBS containing 1% Triton X-100 or 4% Triton X-100 (for sarkosyl solubilization) 




The bound protein was then eluted using elution buffer (10 mM reduced glutathione, 50 mM 
Tris-HCl, pH 9.0) with the fractions being collected until an A280 of 0.02 was again reached. 
The unbound fraction as well as all eluted fractions were then analysed for protein on an SDS-
PAGE gel. The column was then regenerated using five column volumes of sodium borate 
buffer (200 mM sodium borate, 500 mM NaCl, pH 8.0), followed by five column volumes of 
dH2O, then five column volumes of sodium acetate buffer (100 mM sodium acetate, 500 mM 
NaCl, pH 4.0) then finally being stored in storage buffer (500 mM NaCl with 1 mM NaN3) at 
4°C. This purified, uncleaved rBACE1-GST was analysed using an SDS-PAGE and western 
blot after which it was used for immunization of chickens for antibody generation. 
2.2.7 Bradford Assay 
A Bradford protein assay was then carried out on each eluted fraction in an effort to determine 
the concentration of the eluted protein. This assay was carried out using a NanoDrop 2000 
spectrophotometer. A protein standard curve was made using a stock solution of 1 mg/ml BSA 
to prepare protein standard solutions ranging from 30 to 200 μg/ml, with all readings carried 
out in triplicate. Protein standards were mixed 1:1 with Bradford reagent (Thermo Fisher 
Scientific, USA). The absorbance at 595 nm was measured after incubation in the dark for 10 
mins (Bradford, 1975). 
2.2.8 Cleavage of GST-tag using thrombin 
A comparison was made between on-column thrombin cleavage and off-column thrombin 
cleavage. For the on-column thrombin cleavage, the glutathione-agarose column was 
equilibrated with ten column volumes of PBS pH 7.4, containing 4% Triton X-100. The 
refolded and diluted rBACE1-GST was then added to the column and incubated for one hour 
at room temperature rotating on an end-over-end rotator. The column was then washed with 
PBS pH 7.4, containing 4% Triton X-100 with the eluent being collected in 1 ml fractions. The 
OD of each fraction, at 280 nm, was measured with fractions being collected until an OD of 
0.02 was reached. After this the column was equilibrated with 20 column volumes of thrombin 
cleavage buffer (20 mM Tris-HCl, 150 mM NaCl, 2.5 mM CaCl2, pH 8.4). After equilibration 
the column was resuspended in 1 ml thrombin cleavage buffer containing 2 U thrombin 
(MilliporeSigma, USA). The resin was then incubated at 4°C for 16 h on an end-over-end 
rotator. After this, the column was washed with ten column volumes of thrombin cleavage 
buffer with 1 ml fractions of eluent being collected. The column was then washed with ten 
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column volumes of elution buffer to elute any remaining fusion protein as well as the bound 
GST. The column was then regenerated as previously described.  
 
For the off-column thrombin cleavage, protein was eluted from the column as outlined prior. 
After the eluted fractions were pooled, a buffer exchange step was then carried out through the 
use of dialysis. The pool was placed into MWCO 10 000, Snakeskin™ dialysis tubing (Thermo 
Fisher Scientific, USA) and was dialyzed against 100 x volume of PBS for two h at 4°C with 
gentle stirring. This was followed by a further two hour dialysis against fresh PBS after which, 
a final overnight dialysis was carried out. After dialysis, thrombin was added to the purified 
protein at a final thrombin concentration of 10 units per mg of purified protein. This was then 
left to incubate overnight at room temperature. With the cleavage reaction being stopped with 
1 mM phenylmethane sulfonyl fluoride (Thermo Fisher Scientific, USA). The thrombin was 
then removed through the use of a HiTrap Benzamidine FF column (MilliporeSigma, USA). 
The prepacked 1ml column was washed with 5 column volumes of distilled water, equilibrated 
with 5 column volumes binding buffer (50 mM PBS, 500 mM NaCl, pH 7.4). The protein pool 
was then added to the column at a steady rate of 1 ml/min. The column was washed with binding 
buffer with all fractions being analysed for protein content using absorbance at 280 nm. All 
fractions with A280 readings above 0.02 were pooled. The resulting protein pool was then rerun 
over the glutathione-agarose column (MilliporeSigma, USA) as before.  This time however, the 
unbound fractions were collected and pooled. The resulting pool was then concentrated using 
a Centricon 30 000 MWCO centrifugal concentrators (Amicon, MilliporeSigma, USA; 
centrifuging at 4000 xg, 5 mins, 4°C). 
2.2.9 Gelatine gel zymography 
A gelatine gel zymogram was run identically to the SDS-PAGE gels described previously, with 
the addition of 0.1% gelatine to the running gel buffer prior to setting. After electrophoresis, 
the gel was washed in two changes of 2.5% Triton X-100 for 30 mins each. This was followed 
by incubation at 37°C overnight in sodium acetate buffer (50 mM acetate, pH 4.5). The gel was 
then stained using Coomassie stain as described for the SDS-PAGE gels before. Protease 
activity was detected by the presence of a clear band where gelatine degradation had occurred 
(Tam et al., 2004). A positive control was carried out using a recombinantly expressed BACE1 
produced in HEK-293 cells (MilliporeSigma, USA). 
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2.3 Production of anti-BACE1 and anti-GST IgY antibodies 
2.3.1 Chicken immunization with rBACE1-GST 
The use of all animals for research was approved by the Biomedical Research Ethics Committee 
(053/15/Animal) at the University of KwaZulu-Natal. A single chicken was injected 
intramuscularly with 750 µl of protein-adjuvant solution, once per breast. For the first 
immunization, Freund’s complete adjuvant (MilliporeSigma, USA) was mixed 1:1 with 
uncleaved rBACE1-GST solution, bringing the concentration of the rBACE1-GST protein to a 
final concentration of 100 µg/ml. The boosters that followed were carried out on weeks 2, 4 
and 6, using Freund’s incomplete adjuvant (MilliporeSigma, USA). Injections were carried out 
using a 2 ml syringe with a 20-gauge needle after sterilizing the surface of the breast with 70% 
(v/v) ethanol. Eggs were collected daily for 12 weeks, with an egg being collected on the day 
of first immunization as a pre-immune control. 
2.3.2 Separation of IgY antibodies from chicken eggs 
The separation of IgY from the proteins in chicken egg yolk was carried out as per Goldring 
and Coetzer, 2003. Briefly, the egg shell was carefully removed and the white discarded. The 
yolk sac was punctured and separated from its contents and the yolk volume was measured. 
The yolk was then mixed with phosphate buffer (100 mM Na2HPO4, 0.02% (w/v) NaN3, pH 
7.6) equal to twice the volume of the yolk. PEG 6 000 was then added to a final concentration 
of 3.5% (w/v). This was then centrifuged at 4 420 xg for 30 mins at 4°C. The pellet was 
discarded and the supernatant filtered through cotton wool. To this filtrate, additional PEG 
6 000 was added to bring the total concentration up to 12% (w/v). This filtrate was then 
centrifuged at 10 000 xg, for 20 mins, at 4°C. The supernatant was then discarded and the pellet 
dissolved in phosphate buffer equal to the original yolk volume. To this, 12% PEG 6 000 was 
added and the solution centrifuged at 10 000 xg, for 20 mins, at 4°C again. The supernatant was 
again discarded and the pellet was then dissolved in phosphate buffer containing 0.1% (w/v) 
NaN3. The protein concentration of this solution was then determined by measuring the A280.  
2.3.3 Enzyme-Linked Immunosorbent Assay 
For the enzyme-linked immunosorbent assay (ELISA), each well of a 96 well microtitre plate 
(Corning, USA) was coated overnight at 4°C, with 150 µl of a 1 µg/ml solution of BACE1-
GST in coating buffer (50 mM NaHCO3, pH 9.6). The plate was then blocked with PBS-BSA 
for one hour at 37°C, using a total of 200 µl/well. The plate was then washed with PBS-Tween 
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three times. After drying, 100 µl of a 1 mg/ml solution made using the crude antibody sample 
collected prior, was added to each well as the 1° antibody, this was then incubated for one hour 
at 37°C.  
 
The 1° antibody was discarded and the plate washed again with PBS-Tween three times 
followed by the addition of the 2° antibody (rabbit anti-chicken IgY conjugated to HRPO) 
(MilliporeSigma, USA) at a dilution of 1:10 000 (120 µl/well). This was again incubated for 
one hour at 37°C after which the plate was washed again using PBS-Tween. A solution of 
1 mg/ml Tetramethylbenzidine (TMB, VWR Life Science Amresco Biochemicals, USA) was 
diluted 1:10 in citrate-phosphate buffer (0.15 M, pH 5.0) after which H2O2 (MilliporeSigma, 
USA) was added to a final concentration of 0.0015%. A total of 150 µl of this TMB solution 
was then added to each well and the plate was stored at room temperature in the dark for 30 
mins. The presence of anti-BACE1-GST antibody was then detected through the measurement 
of absorbance at both 652 nm using a SpectraMax ABS plate reader (Molecular Devices, USA). 
2.3.4 Purification of anti-GST and anti-BACE1 IgY 
A western blot was performed as before, using 1.5 mm thick gels instead of the 1 mm thick gels 
used prior. The BACE1, GST solution obtained from off column thrombin cleavage was used, 
before the GST had been removed. The maximum amount of solution was added to each well. 
After transferral of the protein from the PAGE gel to the PVDF membrane (Pall Corporation, 
USA), the membrane was activated again by wetting it with methanol. Using the molecular 
weight marker as a guideline, strips of the blot were cut so as to separate the GST and BACE1 
bands respectively. The PVDF strips were incubated in acidic glycine buffer (100 mM glycine, 
pH 2.5) for five mins. This buffer was discarded and washed twice with TBS-Tween for five 
mins each. The membrane strips were then blocked with TBS containing 0.5% (w/v) BSA for 
one hour at room temperature with gentle rocking. The blocking solution was then removed 
and the strips washed with TBS-Tween as before. Crude antibody samples isolated from all 
eggs collected from week seven of immunization were diluted 1 in 5 in TBS-BSA. The 
membrane strips were then incubated in this antibody solution overnight at 4°C with gentle 
shaking. This solution was then removed and the strips washed twice again with TBS-Tween 
followed by a further two washes in PBS. Bound antibodies were then eluted by adding 1 ml 
acidic glycine buffer, followed by a ten min incubation at room temperature. This buffer, 
containing the eluted antibodies was then collected. The pH of this eluent was brought to a pH 
of 8.0 through the addition of 100 µl Tris buffer (1 M, pH 8.0). This elution process was 
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repeated once, bringing the final volume of each antibody solution acquired to 2.2 ml. Antibody 
concentrations were then determined through the measurement of A280 as before. To confirm 
the presence and specificity of these antibodies, western blots were carried out against both 
rBACE1 and GST. 
2.4 Differential scanning fluorimetry 
2.4.1 Thermal shift assay optimization 
Expression of BACE1-GST was carried out as previously, however a further three column 
volumes of PBS not containing Triton X-100 were used to wash the column with cleavage being 
carried out in PBS. On-column thrombin cleavage was then carried out with the resulting 
protein being used for the DSF assays. Thermal shift assays were carried out using the high-
resolution melting (HRM) mode of the Corbett RG 6 000 thermal cycler (Corbett Research, 
USA) using the Rotor-Gene software (Corbett Research, USA). The concentration of the 
fluorescent protein stain, SYPRO orange (Invitrogen, USA) was first optimized. This was 
carried out by using concentrations of 1X, 5X, 10X and 20X dye with a concentration of 1 µM 
of rBACE1 (Wright et al., 2017). Further, several buffers were tested including sodium acetate 
buffer (50 mM sodium acetate, pH 4.5), PBS as well as acetate, 2-(N-Morpholino) 
ethanesulfonic acid (MES), Tris (AMT) buffer (100 mM acetate, 100 mM MES, 200 mM Tris-
HCl) over a range of pH values (pH 4.0, 5.0, 6.0, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0). All thermal shift 
reactions were carried out with a reaction volume of 25 µl, with measurements being carried 
out between 25 and 95°C. Gain was optimized at the beginning of each experimental run. The 
BACE1 specific inhibitor, Verubecestat, was used as a confirmation for the thermal shift assay 
with the Verubecestat being used at a concentration of 1 µM. Thermodynamic parameters were 
determined for BACE1 from the DSF data using the following equations as per Wright et al., 
(2017). Equation 1 was used to determine the Fmax, the predicted fluorescence intensity when 
the protein in question is fully unfolded. FTm corresponds to the fluorescence measured at the 
recorded Tm and the Fmin corresponds to the lowest fluorescence achieved during the DSF 
assay. Equation 2 was used to determine the proportion of folded protein (Pf) present at each 
temperature with F being the fluorescence measured at the respective temperature. Equation 3 
was used to calculate the proportion of unfolded protein (Pu) at each temperature. The 
equilibrium constant of unfolding (Ku) was then determined using equation 4 allowing for the 
determination of ΔuG (equation 5). A plot of ΔuG against temperature in Kelvin at each 
temperature was then made, with the line of best fit being extrapolated to 298 K to determine 
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the ΔuG˚. Equation 6 was then used alongside the ΔuG˚ value to determine the standard entropy 
of unfolding (ΔuS˚) and subsequently the standard enthalpy of unfolding (ΔuH˚).  
 
𝐹𝑚𝑎𝑥 = (𝐹𝑇𝑚 − 𝐹𝑚𝑖𝑛) + 𝐹𝑇𝑚  (1) 
 



















∆𝑢𝐻 = 𝑇𝑚∆𝑢𝑆 (7) 
2.4.2 Screening of BACE1 against ChemBridge compound library 
The 50 compounds of the in-house compound library obtained from the ChemBridge 
DIVERSet compound collection (ChemBridge, USA) were screened against 1 µM rBACE1. 
The rBACE1 was mixed with 20 µM of each compound and incubated on ice for 30 mins before 
the addition of dye. A control using a concentration of 2% dimethyl sulfoxide (DMSO, 
MilliporeSigma, USA) was also carried out. Binding was detected as a shift in the Tm of the 
rBACE1, characterized as the temperature at which the rate of increase in fluorescence was 
highest. 
2.5 Expression of BACE1 in a mammalian cell line 
2.5.1 Generation of a BACE1 expressing cell line 
HEK-293 cells were obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: HEK-293 Cells from Dr. Andrew Rice (catalogue number: 103). These cells were 
thawed and subsequently grown and maintained in growth media (90% (v/v) Dulbecco’s 
Modified Eagle’s Medium (DMEM, 10% (v/v) foetal bovine serum (FBS) and 0.2× penicillin-
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streptomycin (PenStrep) all purchased from Thermo Fisher Scientific, USA) at 37°C in 5% CO2 
in T75 flasks. Cells were then washed twice with 10 ml sterile PBS and exposed to three ml 
0.25% (w/v) trypsin for two mins at room temperature. After visually confirming all cells had 
been successfully detached from the flask surface, 3 ml growth media was added. The resulting 
mixture was then centrifuged at 1000 xg for 5 mins with the supernatant being discarded. The 
cell pellet was resuspended in growth media and 5 x105 cells were seeded into each well of a 
24 well-plate and grown until 90% confluence under identical conditions as before. Once these 
cells reached 90% confluence, DNA solutions containing 5 µg BACE1-pcDNA-DEST 40 
plasmid, 5 µl PLUS reagent (Thermo Fisher Scientific, USA) in 250 µl Opti-MEM media 
(Thermo Fisher Scientific, USA) were made. Volumes of lipofectamine including 2, 3, 4 and 5 
µl were then diluted in 50 µl each, with each solution then being mixed 1:1 with the DNA 
solutions made prior and incubated at room temperature for five mins. Each resulting 
lipofectamine-DNA solution was then added to duplicate wells of the previously grown HEK-
293 cells, at a final volume of 50 µl (final concentrations per well: 500 ng DNA, 1-2.5 µl 
lipofectamine). A mock-transfected control was carried out, as well as a transfection using the 
empty pcDNA-DEST 40 plasmid. The cells were then incubated as before for three days, after 
which the media was discarded and replaced with selection media (90% (v/v) DMEM, 10% 
(v/v) FBS, 0.2X PenStrep and 200 µg/ml G418). Growth in the presence of selection media was 
taken as confirmation of transfection. Once confluent, cells were transferred to T75 flasks and 
maintained in selection media. 
2.5.2 Assaying compound cytotoxicity in BACE1 expressing HEK-293 stable cell line 
BACE1 expressing HEK-293 cultures were grown to confluency in selection media and 
subsequently trypsinized with the resulting cell pellet resuspended in one ml selection media as 
previously. A sample of cell suspension was mixed 1:1 with Trypan blue after which cell counts 
and viability were determined using a Bio-Rad TC20 Automated Cell Counter (Bio-Rad 
Laboratories, California, USA). Each well in a 96-well plate was then seeded with 2 ×104 
cells/well. Cells were incubated for four hrs at 37°C in 5% CO2 to allow for the cells to adhere. 
Serial dilutions of test compound ranging in concentration from 200 µM to 1.56 µM were then 
added with the cells then being incubated for a further four days at 37°C in 5% CO2. After 
incubation, 40 µl of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt (MTS) reagent containing phenazine ethosulphate (PES) was 
added to the 200 µl of media in each well, followed by further incubation for one hr. The 
absorbance at 490 nm was then recorded using a SpectraMax ABS Plus microplate reader 
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(Thermo Fisher Scientific, USA). The concentrations at which cytotoxicity resulted in 50% cell 
survival (CC50) were calculated for each compound by plotting the non-linear fit of the data 
acquired using the log(inhibitor) vs normalized response – variable slope function in GraphPad 
Prism 8.4.1 (2019, GraphPad Software, USA)   
2.5.3 Cellular thermal shift assay analysis 
After trypsinization of confluent cultures, cells were harvested by centrifugation at 1000 xg for 
five mins. For initial western blot analysis of the transfected cells to confirm BACE1 
expression, the cell pellet was washed twice with 1 ml PBS and then resuspended in 600 µl 
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, 1x protease inhibitor cocktail, 1 µl/ml DNase 1). This 
was incubated for one hour at 4°C with gentle agitation, after which the sample was centrifuged 
at 10 000 xg for 30 mins at 4°C. The pellet was discarded and the supernatant 
analysedviawestern blot as per section 2.3.2. This was carried out on a transfected cell line, the 
mock transfected cell line as well as the cell line transfected with the empty pcDNA-DEST 40 
plasmid.  
 
In the case of the CETSA, prior to harvesting, cells were exposed to the test compounds for 2 
hrs at 37°C with 5% CO2 (Almqvist et al., 2016). The cells were exposed to 10 µM of test 
compound, in the case of the positive control, 1 µM Verubecestat (Merck & Co., USA) 
purchased from MedChemExpress (USA) (Scott et al., 2016) or 0.035% DMSO in the case of 
the control. After incubation, cells were harvested and cell pellets washed twice with PBS. The 
cell pellets were then resuspended in 900 µl PBS and split into 100 µl aliquots. Seven samples 
were incubated at a temperature range of 40-65°C for 6 minutes using a T100 Thermal cycler 
(Bio-Rad Laboratories, USA). The two control samples were incubated on ice and at room 
temperature respectively. Samples were then allowed to cool to room temperature for 6 mins, 
followed by centrifugation at 5 000 xg, for 5 mins and the supernatant discarded. Each cell 
pellet was then resuspended in 50 µl RIPA buffer (MilliporeSigma, USA) for 15 mins at 4°C 
with gentle agitation. After lysis, samples were centrifuged at 10 000 xg for 20 mins at 4°C, 
with the resulting supernatant being analysed by SDS-PAGE, followed by western blotting as 
per Section 2.3.2. using anti-BACE1 rabbit IgG (MilliporeSigma, USA, SAB2108415-100UL) 
(1:1000) followed by goat anti-rabbit IgG conjugated to horse radish peroxidase 
(1:10 000)(MilliporeSigma, USA, AP156P). Visualization was carried out using enhanced 
chemiluminescent substrate (ECL) (Clarity ECL reagent, Bio-Rad Laboratories, USA) and 
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viewed with a G:BOX Chemi XR5 (Syngene, India) in the GeneSys software (2012). 
Densitometry was then carried out on the bands corresponding to monomeric BACE1 in all 
samples using the ImageJ 1x software (Schneider et al., 2012). The relative intensity values 
were then normalized into percentages with the largest intensity for each sample assigned a 
value of 100% and the lowest assigned as 0%. Data was plotted using a Boltzmann sigmoidal 
function calculating the Tagg using GraphPad Prism 8.4.1.  
2.6 Zebrafish embryo toxicity test 
All zebrafish studies were carried out with ethics approval (AREC/029/019) being granted for 
the project entitled: “Establishment of Zebrafish models for the study of human disease and 
toxicology” on 3 June 2020.12.03 attached in Appendix A. Zebrafish (Danio rerio) were 
sustained in tanks of aged water at a temperature of 28°C under the illumination of blue light 
(wavelength ~450 nm). Fish were fed three times per day with TetraPro Energy fish flakes 
(Tetra, Germany) at regular six hourly intervals. Male fish were mixed with females at a ratio 
of 1:2 the afternoon prior to breeding with collection reservoirs being placed in each tank. 
Breeding was allowed to take place for 30 mins after the onset of light. Fertilized embryos were 
then taken, washed using E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM 
MgSO4, 5% Methylene Blue) and subsequently separated into 24-well plates at 10 
embryos/well. A positive control using 4 mg/l 3,4-dichloroaniline (MilliporeSigma, USA) was 
used alongside negative controls containing DMSO as well as a control containing E3 media 
only. Embryos were exposed to compounds over a concentration range at three hrs post-
fertilization (hpf) and incubated at 28.5°C. Concentration ranges were determined using a 
range-finding test whereby embryos were exposed to compounds at concentrations of 100 
mg/L, which were subsequently diluted until 100% survival was recorded. Images of embryo 
development for each embryo were taken at 24, 48, 72, 96 hours post fertilization and five days 
post fertilization (dpf). Lethality and proportion of embryos presenting abnormalities were 
recorded and used to determine LC50 values as well as teratogenicity for test compounds. For 
teratogenicity, the concentration at which no abnormalities in embryo development was 
determined using an established scoring system based on the appearance of nine morphological 
endpoints. These endpoints include somite formation, notochord formation, tail structure, fin 
structure, heart shape, brain segmentation, facial structure and jaw structure and pharyngeal 
arch structure. A score up to 5 was assigned based on the level of abnormality from the correct 
morphology with 5 being allocated to correct morphology and a minimum score of 0.5 
indicating a total lack of the structure in question, resulting in a maximum possible score of 45 
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in accordance with Panzica-Kelly et al. (2010). Whether a compound was teratogenic or not 
was determined by calculating the ratio between the LC50 and the EC50 both of which were 
calculated using a nonlinear regression using GraphPad Prism 8.4.1 (2019, GraphPad Software, 
USA). If this teratogenic index was greater than 1 the compound was deemed teratogenic 
whereas all compounds scoring teratogenic indexes less than 1 were denoted as not being 
teratogenic (Panzica-Kelly et al., 2010) (Alafiatayo et al., 2019). 
  
2.7 Computational analysis of the BACE1 protein structure 
The Schrodinger Biologics suite (2018-2) (Schrodinger, USA) was utilized for all in silico 
analysis. Docking experiments were carried out using the 3D human BACE1 protein structure 
5HU1. To prepare the protein structure, the protein preparation wizard was used. All water 
molecules found further than 5 Ǻ from the bound ligand were deleted, heteroatom states were 
generated using Epik with a chosen pH of 7.0. Missing hydrogens were added, bond orders 
assigned and disulphide bonds generated. After this, hydrogen bond assignments were 
optimized and the resulting structure was then minimized. Ligands to be screened were drawn 
using the 2D sketcher tool and were prepared using the LigPrep function to add missing 
hydrogens and generate possible conformations of the ligands. At most 32 conformations were 
generated per ligand and Epik was used to generate protonation states. The prepared BACE1 
protein was then used to create a receptor grid through the use of the receptor grid generation 
tool. No constraints were used. The resulting receptor grid model was validated through 
redocking of its cognate ligand back into place. The root-mean-square-deviation (RMSD) value 
of the conformation with the highest Glide score against the original, bound ligand was 
calculated with the model being validated by an RMSD value of one or less. Screening of the 
in-house compound library against the prepared receptor grid was initially carried out using 
standard precision (SP), after which all hits scoring a Glide score below -5 were then screened 
again, using extra precision (XP) (Kumar et al., 2017). All resulting hits with a Glide score less 
than -5 were assessed individually to determine which amino acids were involved in binding, 
with the ligands that demonstrated bonding to either of the catalytic aspartate residues being 
selected as successful hits. This was carried out on the BACE2 crystal structure 2EWY as well. 
Further binding sites on the BACE1 protein were determined using the SiteMap tool, with 
residues found in the discovered binding site. A receptor grid was generated for any potential 
binding site as before, however without the redocking steps, with screening taking place only 
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on XP setting, with all conformations exhibiting a Glide score less than -5 being accepted as 
binders.  
 
2.8 In Silico screening of the Enamine REAL database for BACE1 binding compounds 
The structure of compounds detected to bind BACE1 in the DSF screening, CETSA and 
molecular modelling simulations were then used to screen the Enamine REAL database 
(Enamine, Ukraine) for similar compounds using the MadFast Similarity Search (ChemAxon, 
Hungary, https://www.enaminestore.com/search accessed last on 14/06/2019). Compounds 
possessing similarity scores of greater than 0.6 in the database were then screened in silico for 
BACE1 binding as per Section 2.8. The compound scoring the lowest Glide score was then 
used to search for more similar compounds with this process being carried out a total of five 
times. The compound detected to have the highest propensity for binding BACE1 as indicated 
by the lowest Glide score at the end of the fifth screening was then assayed for intracellular 
binding of BACE1 using the CETSA as per Section 2.6.3. 
 
Test compounds were also assessed for predicted drug likeness alongside other relevant traits 
using the in silico tools SwissADME, Aggregate advisor and OSIRIS property explorer. 
Aggregate advisor was accessedviahttp://advisor.bkslab.org/  (Irwin et al., 2015) in December 
2020. SwissADME was accessedviahttp://www.swissadme.ch/ last accessed in December 
2020. OSIRIS property explorer was accessedviahttps://www.organic-chemistry.org/prog/peo/ 
last accessed in December 2020. 
 
2.9 Statistical analysis 
All statistical analyses were carried out using PSPP (GNU Project, USA). Significance is 
represented with a p-value < 0.05 using a two-tailed Student’s T-test. 
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CHAPTER 3: RESULTS 
3.1. Confirmation of presence of pGEX4T-1 containing the rBACE1 gene in transformed 
Escherichia coli BL21 DE3 cells  
 
Prior to plasmid synthesis, the human BACE1 gene was analysed for possible restriction 
endonuclease sites using NEBcutter (Appendix B). Based on this analysis it was decided that 
the gene would be synthesized between the cleavage sites of EcoR1 and BamH1. The protein 
sequence was analysed using PeptideCutter to determine possible cleavage sites of common 
proteases (Appendix C). Neither Factor Xa nor thrombin cleavage sites were present and thus 
the BACE1 gene was synthesized in a pGEX-4T1 vector as this would allow for the removal 
of the GST tag using thrombin. Competent E. coli BL21 DE3 cells were successfully 
transformed with the BACE143-454–GST plasmid. This was demonstrated by the capability of 
the transformed E. coli to grow on 2xYT agar plates in the presence of 100 µg/ml ampicillin. 
To ensure the E. coli contained the plasmid with the full BACE143-454 gene insert, the plasmid 
was isolated from the transformed bacteria using a GeneJet plasmid DNA isolation kit. The 
plasmid DNA was isolated at a concentration of 296.3 ng/µl with an A260/A280 ratio of 1.99, 
indicating pure DNA to be present. This DNA was exposed to a restriction digestion by the 
restriction enzymes EcoR1 and BamH1 with both the digested and undigested DNA being 
visualized as bands on a 1% (w/v) agarose gel shown in Figure. 3.1. Four distinct bands resulted 
from the restriction digestion of the DNA with EcoR1 and BamH1, present at 1 200, 1 800, 2 
400 and 5 000 base pairs (bp) respectively as seen in Figure 3.1. This indicates the release of 
the rBACE1 gene insert (1 200 bp) from the vector (5 000 bp; lane 1). These bands indicate 
that contaminating plasmid DNA may have been present within the transformed bacteria. This 
was further substantiated by the presence of more than three bands in the undigested DNA 
sample. The undigested DNA appears in seven bands ranging from 3 500 to greater than 10 000 
bp in size (lane 2). Due to this anomalous plasmid DNA the isolated plasmid was also sent for 
gene sequencing (Inqaba Biotec, RSA) which confirmed the presence of the BACE1 gene 







represented by the prominent bands at 70 kDa in lanes 3 and 4 of Figure 3.3, panel A. In the 
remaining samples, minimal soluble protein was detected. The insoluble fractions however, 
displayed large amounts of protein present at 70 kDa. Densitometry of the western blot 
confirmed the findings of the SDS-PAGE gels indicating that, despite the band present in the 
uninduced samples, the results determined from the densitometry of the SDS-PAGE gels were 
reliable. It was also confirmed the insoluble fraction of the sample obtained from induction in 
the presence of 1% ethanol indeed contained the most rBACE1-GST. Thus, induction at 16°C 
overnight in the presence of 1 mM IPTG was selected for all future experiments. This was 
chosen as, although both LB media and 0.5 mM IPTG resulted in more soluble protein 
exhibiting relative band intensities of 25929.67 and 24273.89 respectively, the largest amount 
of rBACE1-GST was present in the 1% ethanol insoluble fraction allowing for the greatest 
possible protein yields with a relative band intensity of 39061.59. Due to the insolubility of the 
rBACE1-GST, an attempt to reduce insolubility of the protein by disrupting aggregation was 
attempted. The insoluble fractions obtained from expression were exposed to various conditions 
known to inhibit protein aggregation. After separation of the insoluble and soluble fractions, 
the insoluble fraction was resuspended and sonicated to disrupt remaining protein aggregates. 
An SDS-PAGE gel was then run on the resulting samples (Figure. 3.4). None of these 
conditions resulted in increased solubility however, indicating that the insolubility observed 











the use of an ELISA, the week in which the most antibodies against rBACE1-GST were 
produced was determined to be week seven (Figure 3.7). High background readings were 
present in the pre-immune sample. The eggs produced one week after immunization exhibited 
a consistent increase in TMB signal when analysedviaELSIA indicating an increase in the 
production of anti-rBACE1-GST antibodies. Signal was significantly higher than that of the 
pre-immune sample from week 3 onwards, up until week 11, however after week seven, the 
signal began decreasing, corresponding with the final booster on week six. The signal plateaued 
for the remaining weeks. Accordingly, anti-BACE1 and anti-GST antibodies were isolated from 
the eggs produced during the seventh week of immunization so as to generate the highest 
concentration of antibody possible.  
3.3.2. Purification of anti-BACE1 and anti-GST IgY  
The concentration of the antibodies affinity-purified using rBACE1 and GST bound to 
nitrocellulose from week seven was then determined through measurement of A280. The 
concentration of the anti-BACE1 IgY antibodies was 0.272 mg/ml and the anti-GST IgY 
antibodies to be 0.254 mg/ml using an extinction coefficient of 1.25 (Goldring and Coetzer, 
2003). Antibodies purified this way were then used in a western blot against a purification 
profile of rBACE1 to confirm specificity as shown in Figure. 3.8. One band was detected at the 
predicted size of the cleaved rBACE1 in the final purified sample and was also detected in the 
western blot. The rBACE1 ran at a size of approximately 50 kDa which is in alignment with 
the predicted size of 46 kDa in both the SDS-PAGE gel as well as the western blot. In panel C, 
lane 7, the chicken anti-GST IgY antibody did not detect this protein, further indicating 
successful removal of the GST-tag. In the same lane, the chicken anti-GST IgY antibody 
detected a protein at 20 kDa, assumed to be remaining GST-tag. This was not visible in the 





Figure 3.7: Enzyme-linked immunosorbent assay analysis of anti-BACE1-GST antibody production in 
chickens over the course of immunization. Microtitre plates were coated with 1 µg/ml of pure BACE1-GST. 
The total IgY fraction isolated from an egg from each week of immunization was used as the primary antibody at 
a concentration of 1 mg/ml. A goat anti-chicken IgG antibody conjugated to horseradish peroxidase was used as a 
secondary antibody (Advansta, USA). The substrate used was 3,3',5,5'-Tetramethylbenzidine with absorbance 
readings being read at wavelengths of 652 nm. Error bars represent standard deviations of triplicate samples. 
Samples with readings significantly higher than the pre-immune sample signal are representedviaasterisks, with 
significance being determined utilizing a p-value of 0.05. 
3.4.Confirmation of mammalian BACE1 detection in HEK-293 cells by purified anti-
BACE1 IgY  
 
The chicken anti-BACE1 IgY antibodies detected BACE1 in the HEK-293 cells demonstrating 
the ability to detect BACE1 despite post-translational modifications, as shown in Figure 3.9. 
BACE1 was present in the lysates of the HEK-293 cells that were transfected with the BACE1-
pcDNA-DEST 40 plasmid as well as the HEK-293 cells transfected with the empty pcDNA-
DEST 40 vector. The mock transfected HEK-293 cells also displayed BACE1 expression. This 
was expected as BACE1 is known to be expressed in HEK-293 cells (Schaefer et al., 2016). 
Protein bands at 65 and 110 kDa were present in all lysates corresponding to the sizes of the 
BACE1 monomer and dimer respectively. Two protein bands corresponding to sizes around 
35-30 kDa were also detected by the chicken anti-BACE1 IgY antibodies. These sizes do not 
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where it was determined that BACE1 is in an inactive conformation at this pH which resulted 
in increased thermostability which is potentially why a defined peak was detected at this pH. It 
is however unclear why no peak was detected from the rBACE1 at this same pH in the AMT 
buffer, although it is possible that the buffer transfer process might have resulted in denaturation 
resulting in a lack of a defined peak. An alternative theory is that the components of the AMT 
buffer may be affecting the protein structure directly as it has been seen that buffer components 
can affect protein dynamics in solution (Long and Yang, 2009), however this has not been 
reported in molecular dynamics of protein folding. The Tm value of rBACE1 was 82 ± 0.21°C 
in the absence of Verubecestat. This is similar to the recorded Tm of 84°C of BACE1 produced 
in mammalian cells at pH 7.4 (Hayley et al., 2009). It is important to note that the Tm reported 
by Hayley et al. was an estimate of 84°C as a result of the limitations of the circular dichroism 
spectroscopy used, whereas the Tm detected in this study was within the limits of detection of 
the DSF experiment. The presence of a shift in Tm from 82 to 84.15 ± 0.28°C when in the 
presence of Verubecestat confirmed that the rBACE1 model could be used to screen for binding 
molecules. This shift was confirmed to be statistically significant (p-value < 0.05), with 
experiments being run in duplicate. The melt curves were then used to determine the ΔuG of 
the rBACE1 protein in PBS, at each temperature interval using equations 1 to 5, plotted in 
Figure 3.11. Data was extrapolated to 298 K to determine the ΔuG˚. It was observed that the 
coefficient of determination (R2) for the line of best fit was 0.934 ± 0.007 for BACE1 in the 
absence of Verubecestat. In the presence of Verubecestat the R2 value was calculated at 0.733 
± 0.06 indicating that BACE1 does not undergo single-step equilibrium unfolding, while in the 
presence of Verubecestat. As a result, the ΔuG˚ for BACE1 in the presence of Verubecestat 
could not be calculated. The ΔuG˚ of BACE1 in the absence of Verubecestat was then used to 
calculate the corresponding standard ΔuS˚ and ΔuH˚ of unfolding, as per Wright et al, 2017. For 
BACE1 in PBS, the ΔuG˚ was calculated to be 112 ± 0.1 kJ/mol, the ΔuS˚ was 1.82 ± 0.002 
kJ/mol K and ΔuH˚ was 642 ± 0.7 kJ/mol. These values are higher than those of the proteins 
studied by Wright et al, such as the values reported for carbonic anhydrase, chymotrypsin, 
lysozyme and peroxidase. The values of which ranged from 20.7 ± 0.3 to 60.4 ± 0.6 kJ/mol for 
ΔuG˚, 0.63 ± 0.0.01  to 1.60 ± 0.02 kJ/mol K for ΔuS˚ and 212 ± 5 to 536 ± 6 kJ/mol for ΔuH˚ 
values, all of which are lower than the values reported in this study for rBACE1, indicating high 






Figure 3.10: The melting profile of 1 µM rBACE1 in the presence and absence of 1 µM of the BACE1 specific 
inhibitor, Verubecestat. The plot of the derivative of the relative fluorescence of SYPRO orange dye in the 
presence of the rBACE1 protein only, as well as rBACE1 in the presence of Verubecestat over the temperature 
range of 25-95°C is displayed. Samples were assayed in duplicate. 
 
Figure 3.11: The change in Gibbs energy of unfolding of BACE1 during protein unfolding over the course 
of a differential scanning fluorimetry assay. Gibbs energy (ΔuG) was calculated using the fluorescence values 
from the linear phase of the melt curve. Values were then extrapolated to 298 K to determine the standard Gibbs 
energy of unfolding (ΔuG˚). The equation for the line of best fit is: y=-1809.9x + 642673. The coefficient of 
determination (R2) was equal to 0.9388. The insert highlights the region of the graph generated by the differential 























3.5.2. Screening of the ChemBridge compound library subset against rBACE1 
The rBACE1 was screened against 50 compounds from the ChemBridge compound library with 
the compounds at a final concentration of 20 µM during the assay, with the resulting Tm values 
represented in Figure 3.12. In the presence of 2% DMSO, the Tm of the rBACE1 decreased 
from 82°C to 75.4 ± 0.64°C indicating that DMSO has a destabilizing effect on rBACE1. This 
diminishing effect of DMSO on thermostability has been reported previously, where it was 
found to reduce the thermostability of lysozyme (Magsumov et al., 2019). It has been suggested 
by Yu et al, in 2016, that this effect of inorganic solvents on protein thermostability is not the 
result of a disruption of secondary protein structures, but the skewing of the proportion of 
unfolding protein states in equilibrium which results in a decreased amount of energy being 
required to push this equilibrium in favour of unfolded protein states (Yu et al., 2016). This 
reduction in thermostability may potentially reduce the accuracy of the assay if this equilibrium 
is sufficiently skewed to unfolded protein states, as it would result in an elongated, lower 
intensity, signal peak leading to higher deviations in compounds only capable of binding certain 
conformations of the partially folded protein. In contrast, compounds exhibiting binding 
capability for many conformations would still exhibit low variance. In the presence of both 
DMSO and Verubecestat, the Tm of rBACE1 increased from 75.4°C to 77.76 ± 0.15°C. It was 
also noted that ΔuG˚ could not be calculated for BACE1 in the presence of DMSO due to lack 
of linearity when ΔuG was plotted against temperature. 
 
Ten compounds induced a statistically significant negative shift in Tm using a p-value of 0.05 
as depicted in Figure 3.12. A negative ∆Tm is indicative of a ligand binding to a state of the 
protein with lower stability than its native form (Kabir et al., 2016) and thus any compounds 
resulting in apparent negative shifts were disregarded. Overall, three compounds induced 
positive, statistically significant thermal shifts indicating possible binding (p-value < 0.05). The 
names and structures of these compounds are shown in Table 3.2 alongside Verubecestat. The 
∆Tm of Verubecestat was 2.355 ± 0.66˚C. The ∆Tm of C19, C34 and C39 were 2.4± 0.65, 





Figure 3.12: The ∆Tm of rBACE1 brought about by the presence of various compounds. Test Compounds 
were screened against rBACE1 using differential scanning fluorimetry to determine any change in the Tm of 
rBACE1. Denaturation was measured through the use of the SYPRO orange dye over the temperature range 
between 25 and 95°C. Data is presented as the difference in melting temperature (Tm) of rBACE1 in the presence 
of 2 µM compound, compared to the Tm of rBACE1 of 75.4°C. Error bars represent standard deviations of 
duplicate samples. Samples exhibiting Tm values significantly different to the rBACE1 sample are 
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Table 3.2: Compounds which result in a positive thermal shift in rBACE1 as detected by 















3.6 Screening for intracellular ligand binding using the cellular thermal shift assay 
3.6.1 Assaying for cytotoxicity of BACE1 binding compounds in BACE1-overexpressing 
HEK-293 cell line 
In preparation of the CETSA in the BACE1-overexpressing HEK-293 cell line, cytotoxicity of 
all three compounds identified in Section 3.5.2. was determined. In Figure 3.13, no compound 
exhibited a cytotoxic effect great enough to decrease cell viability below 50% at the 







Figure 3.14: Representative western blot for the cellular thermal shift assay carried out on intracellular 
BACE1 overexpressed by HEK293 cells after exposure to 0.025% dimethyl sulfoxide.  The western blot 
resulting from the cellular thermal shift assay of monomeric beta-site APP cleaving enzyme-1 (BACE1) expressed 
in human embryonic kidney-293 cell line (HEK293) after exposure to dimethyl sulfoxide (DMSO). The lane 
containing Spectra™ Multicolor Broad Range Protein Ladder (10–260 kDa) molecular weight marker (MWM), 
the lane containing the control sample exposed to ice (ICE) and the control sample exposed to room temperature 
(RT) as well as the lanes corresponding to the samples exposed to the 40 – 65°C temperature range are indicated. 
Arrows indicate the protein bands at >260 kDa, ~130 kDa, ~65 kDa and ~60 kDa. 
 
The results from the CETSA analysis of BACE1 after exposure of the BACE1 expressing cell-
line to the test compounds is indicated in Figure 3.15. The melt profile for the monomeric 
BACE1 was plotted using a Boltzmann sigmoid distribution after calculating the relative 
intensities of each band for each test compounds, shown in Figure. 3.15B, with the Tagg being 
calculated. The Tagg in the presence of DMSO alone was 49.53 ± 0.69°C. After it was confirmed 
that the CETSA was indeed capable of determining the Tagg of BACE1 in the HEK-
293_BACE1 cell line, Verubecestat as well as the three test ligands, C19, C34 and C39, were 
assayed for intracellular binding using an identical set up.  In the presence of Verubecestat, the 
Tagg of monomeric BACE1 was 53.27 ± 0.89°C, an increase in 3.74 ± 1.13°C of the Tagg as 
compared to BACE1 exposed to DMSO only. This increase was expected as it is known that 
Verubecestat is capable of binding BACE1 intracellularly. The resulting western blots for the 
test compounds displayed similar banding patterns, with regards to the monomeric BACE1, as 
shown in Figure 3.15A. The melt profiles were generated as seen in Figure 3.15B. The Tagg 












3.7. In silico molecular docking 
3.7.1. Generation of an in silico BACE1 model 
A BACE1 model was prepared using Schrodinger Biologics suite (2018-2) using the PDB 
structure 5HU1. The 3D structure of 5HU1 was chosen as it contained BACE1 co-crystallized 
with Verubecestat. After preparation, the model was validated through redocking, shown in 
Figure 3.16, with the redocked Verubecestat exhibiting an RMSD value of 0.9680 when 
compared with the co-crystalized Verubecestat. This was taken as confirmation that the model 
was sufficient for ligand screening. 
3.7.2. Screening of the ChemBridge compound library against BACE1 receptor model 
After validation, the BACE1 model was used to screen the in-house subset of the ChemBridge 
compound library for potential binding molecules. Initially all compounds were prepared and 
docked to BACE1 using the SP setting. After this, all hit compounds with Glide scores below -
5 were then screened against BACE1 again using the more precise XP docking, again 
disregarding any hit compounds with Glide scores above -5. The interactions between these hit 
compounds and the amino acids of BACE1 were then assessed individually for each hit with 
any compounds that did not bind to either of the catalytic aspartates being disregarded. This 
was carried out as binding to the catalytic aspartate dyad is integral for classical inhibition of 
BACE1. The resulting ligands are summarized in Table 3.3 below. 
 
Only five compounds, with a total of nine conformations, from the ChemBridge in-house 
library bound to either of the catalytic aspartates. Only one conformation, that of C10 (2-(3-
chlorophenoxy) propanohydrazide) bound to both aspartates. Both C19 and C34 were detected 
as being potential binders to the BACE1 catalytic site, shown in Figure 3.17, corresponding to 
the results of the DSF experiments. It was also noted that while C34 scored the lowest Glide 
score, it was detected as only binding to Asp289, whereas two conformations of C19 were 
detected, each binding to a different aspartate. Compound 39 did not appear to bind at all, 
however, which suggests C39 binds to BACE1 at a site other than the catalytic site. This lack 
of catalytic site binding calls into question the inhibitory capability of C39, necessitating the 
need for a BACE1 activity assay for further characterization, should C39 appear to be an 
attractive drug candidate. When comparing C3, C10 and C23 to their corresponding DSF 
results, it was noted that the DSF experiment directly contrasted the docking results as C3, C10 










being observed at a concentration of 54.5 µM. It was noted that toxicity of C19 was observable 
after the first 24 hours, with only exposure of 14.6 µM C19 exhibiting a significant increase in 
lethality in the subsequent 96 hours. This indicates that not only is C19 capable of penetrating 
the chorion, but also that it is toxic primarily to the unformed embryo, as after hatching at 
around 72 hours, no further increase in lethality is observed. Compound C34 was less lethal 
than C19 with significant lethality (compared to the control) observed at a concentration of 64.3 
µM. A concentration of 171.4 µM, C34 resulted in 0% survival of the embryos by day five. In 
contrast to C19, C34 was seen to exhibit toxicity throughout the five-day incubation period 
with 107.1, 128.6 and 171.4 µM each exhibiting significantly lower survival percentages from 
72 to 96 hpf. This increase in lethality after hatching was observed despite C34 clearly being 
capable of entering the chorion, evidenced by the significant decrease in survival seen at 24 
hpf, after exposure to 64.3, 85.7 and 107.1 µM. It was also noted that of the three initial test 
compounds that were tested, C34 displayed the lowest toxicity with a concentration of 42.9 µM 
resulting in no significant decrease in survival of the embryos at day five. In contrast to C34, 
C39 was seen to possess the greatest toxicity among the test compounds, resulting in 0% 
survival at a concentration of 7.85 µM, with no significant decrease in embryo survival only 
being detected at a concentration of 1.96 µM as compared to the control. It was also detected 
that this toxicity, similarly to C19, was only observed prior to hatching, with no change in 
survival being detected after 24 hours after exposure to 1.96 or 3.93 µM of C39. Only exposure 
to 7.85 µM C39 yielded a significant decrease in survival in the 24-hour period between 24 and 
48 hpf, with total lethality being observed at 72 hpf. This indicates that C39 is highly toxic to 
unformed embryos but after hatching, embryos develop unimpeded.  
 
For each compound, an LC50 value was calculated using a nonlinear regression function, with 
LC50 values for C19, C34 and C39 being calculated as 26.125 ± 2.45, 127 ± 9.9 and 4.52 ± 0.61 
µM respectively. These values are of interest as the positive control for the zebrafish lethality 
test, as recommended by the OECD guidelines, is the compound 3,4-DCA, which has been 
reported to possess an LC50 value of 19.8 µM, indicating C39 possesses a far greater toxicity 
to that of 3,4-DCA. C19 was also observed to be toxic, possessing a 25% greater LC50 as 
compared to 3,4-DCA. C34 was demonstrated to possess an LC50 value six-fold that of 3,4-
DCA, indicating C34 possesses far lower toxicity than that of the positive control. With regards 
to the Enamine compound C5064, no specific LC50 value was defined as, at the limit of 






Figure 3.24: A fully developed Danio rerio zebrafish at five days post fertilization. Zebrafish embryos were 
grown in E3 media until five days post fertilization after which pictures were taken using an Accu-Scope 1906420 
microscope using an Excelis HDS Lite camera and monitor system (Excelis, USA). 
 
The nine endpoints were first examined after exposure to DMSO to create internal points of 
reference specific for the zebrafish used for this study, due to the nature of their origin. The 
somites present in five-day old zebrafish were observed to be clearly defined along the length 
of the tail, on either side of the notochord as displayed in Figure 3.25 A. These clear lines were 
seen to splay out from the centre of the tail as was expected from correctly formed somites. The 
notochord was seen to extend from the frontal region of the swim bladder to the tip of the tail, 
being clearly delineated from the somites along the entire length of the tail as depicted in Figure 
3.26 A. The tail was seen to be straight, without any kinks or protrusions, as demonstrated in 
Figure 3.27 A. All five fins were seen to be correctly developed, with clear smooth edges on 
each of the dorsal fin, along the top of the tail, the ventral fin underneath and the caudal fin 
along the point of the tail, as indicated in Figure 3.28 A. Each pectoral fin on either side of the 





the brain clearly defined, demonstrating the brain had formed correctly. Finally, the 
morphology of the heart was observed with the heart being present in between two indents in 
the base of the fish body. Both the atrial and ventricular chambers were seen to be present in 
the correct proportions as well as evidenced by Figure 3.31 A. All these regions were seen to 
be correctly formed in accordance with current literature attesting to the viability of the 




Figure 3.26: Notochord morphologies in the tails of Danio rerio zebrafish at five days post fertilization after 
exposure to various compounds. Panel A presents the full tail of a zebrafish after exposure to DMSO only, with 
the notochord running along the full length of the tail. Panel B displays a zebrafish exposed to C34 at a 
concentration of 128.6 µM, exhibiting a notochord scoring a three on the morphology scale due to a large decrease 
in definition with the encircled area showing a severe lack of notochord definition.  
 
3.9.3. Determining compound teratogenicity on each morphological endpoint of Danio 
rerio embryos 
After establishing the validity of the zebrafish model, test compounds were assayed in an effort 





concentration of 36.5 µM was seen to result in statistically significant morphological changes 
in the embryos (p-value < 0.05). Compound C34 however exhibited teratogenicity at a range 
of non-lethal concentrations with morphology scores being statistically lower than those of the 
DMSO control at concentrations above 85.7 µM. Exposure to compound C34 resulted in a 
significant effect on the development of eight of the nine structures being examined in 
Figure 3.32. No significant teratogenicity was detected in C39 within the non-lethal 
concentration range (p-value < 0.05). Similarly to the lethality data, no significant teratogenicity 
was observed within the compound’s solubility range. The morphological scores alongside 
lethality of each compound are depicted in Figure 3.33. 
 
At all tested concentrations, C34 resulted in a significant decrease in the morphological score 
of somites resulting in severe lack of definition in the somites of five-day old individuals, 
(Figure 3.25 B). The notochords of five-day old embryos exposed to 107.1 and 128.6 µM of 
C34 developed with regions that were poorly defined as depicted in Figure 3.26 B. The tail was 
the only morphological endpoint that exhibited no significant decrease in integrity as compared 
to the control however several individuals were seen to possess mild kinks in their tails, as 
presented in Figure 3.27 B. Individuals exposed to 107.1 µM C34 developed incorrectly formed 
pectoral fins, however this was not seen in individuals exposed to 128.6 µM C34. This is 
potentially the result of the effect that C34 had on the swim bladders of the fish. The five-day 
old fish exposed to 128.6 µM C34 exhibited deflated swim bladders resulting in several of these 
fish being unable to swim upright, resulting in only the dorsal, ventral and caudal fins being 
clearly visible. The lack of clearly observable pectoral fins potentially resulted in incorrect 
scoring, indicating a weakness in this scoring method, which could suggest that C34 may be 
partially more teratogenic than indicated at this concentration. The fish exhibiting poorly 
developed fins (Figure 3.28 C and D), possess bent, misshapen pectoral fins as well as dorsal 
and ventral fins with irregular edges. Notably the jaws, pharyngeal arches and facial scores 
were all significantly lower in individuals exposed to C34 at concentrations of 85.7, 107.1 and 
128.6 µM, exhibiting misshapen mesenchyme regions, incorrectly proportioned olfactory 
regions, misshapen lower jaws and indistinguishable pharyngeal arches, as depicted in (Figure 
3.29 B). The brain was also affected by the same concentrations as the facial structures, 
particularly with individuals displaying reduced forebrains as compared to those in the solvent 
control, displayed in Figure 3.30 B. Finally, the hearts of individuals exposed to C34 at all non-
lethal concentrations, from 64.3 to 129.6 µM, were significantly malformed, with the most 





Figure 3.28: Fin morphologies in Danio rerio zebrafish at five days post fertilization after exposure to 
various compounds.  The three tail fins from a zebrafish exposed to DMSO are depicted in panel A. Panel B 
presents the top view of the head of the fully developed zebrafish with the pectoral fins visible. Panel C is the top 
view of a zebrafish exposed to 128.6 µM C34, with a deformed left pectoral fin, which has been encircled, resulting 
in a score of three. Highlighted in panel D is a deformed dorsal fin from an individual exposed to 128.6 µM C34, 










however, it was noted that concentrations of C34 at which no significant decrease in total 
morphological score were observed, were still higher than the lethal doses of C19 and C39. 
 
    
 
Figure 3.31: Heart morphologies in Danio rerio zebrafish at five days post fertilization after exposure to 
various compounds.  The profile of the head of a zebrafish exposed to DMSO only centred on the heart. Panel B 
is an example of a zebrafish exposed to 128.6 µM C34 with a heart that is misshapen and swollen, necessitating a 








f   Abbot bioavailability score (Martin, 2005) 
g   Pan assay interference structures (Baell and Holloway, 2010) 
h   Consensus Log Po/w calculated from iLOGP, XLOGP3, WLOGP, MLOGP and SILICOS-IT lipophilicity scores 
(Daina et al., 2014, Lipinski et al., 2001, Wildman and Crippen, 1999) 
i   Topological solubility score (Delaney, 2004) 
j   Topological solubility score (Ali et al., 2012) 
k   Fragment-based solubility score calculated by FILTER-IT program version 1.02 
l   http://advisor.bkslab.org/  (Irwin et al., 2015) 
m  Predictions made utilizing the OSIRIS property explorer 
n OSIRIS score calculated based off of predicted scores for cLogP, logS, molecular weight, mutagenicity, 
tumorigenicity, irritant and reproductive effect scorings  
SwissADME accessedviahttp://www.swissadme.ch/ last accessed in December 2020 






CHAPTER 4: DISCUSSION 
It was the goal of this study to determine if utilizing BACE1 thermostability as a means of 
detecting potential binding molecules was an effective strategy. To accomplish this, first, the 
conditions for the expression of recombinant BACE1 were explored in an effort to determine 
possible rBACE1 yields. Secondly, the produced rBACE1 was assessed for its usability in a 
compound screening assay utilizing its thermostability as a means to detect protein-ligand 
binding. Thirdly, an in silico BACE1 ligand screening assay was compared to the assay 
successfully developed in objective two to determine its reliability in later stages of the study. 
Fourth, the utility of intracellular BACE1 thermostability as a means to determine intracellular 
protein-ligand binding was assessed using the test compounds successfully detected in objective 
two. Fifth, the use of the test compound capable of intracellular BACE1 binding was 
investigated for its potential as a lead compound for development of further, more potent, 
BACE1 binding ligands. Finally, any in vivo toxicity of the test compounds was examined, to 
assess any potential clinical viability. 
4.1. Greater recombinantly expressed BACE1 yields achieved through optimization of 
expression conditions 
A truncated form of the human BACE1 gene was synthesized in a pGEX4T-1 vector. E. coli 
BL21 (DE3) cells were then transformed with this plasmid. The purity of the plasmid was 
assessed using restriction digestion; however, anomalous bands were present in both the 
undigested and digested plasmid samples isolated from the transformed E. coli. This indicated 
that there was potentially contaminating plasmid DNA within the E. coli cells and as a result 
further confirmation of the presence of the correct BACE1 gene was carried out through 
sequencing with the identical sequence to the original GenBank sequence (GeneID: 23621) 
being confirmed to be present in the E. coli cells. Transformed E. coli cultures were grown, and 
expression was induced using IPTG. Expression of rBACE1 was compared under various 
conditions, where expression in LB media yielded the highest concentration of soluble 
rBACE1-GST. It was anticipated that LB media would yield less rBACE1-GST compared to 
2xYT due to less nutrients. The lower overall protein yield could thus result in less aggregation 
and thus less inclusion bodies, resulting in more soluble fraction. In contrast, the largest yields 
of insoluble rBACE1-GST were generated after induction using 0.5 mM IPTG or following 
induction in the presence of 1% ethanol using 1 mM IPTG. Due to this, a combination of the 
two conditions, namely induction with 0.5 mM IPTG in the presence of 1% ethanol, was tested. 
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It was found however, that 16°C overnight induction in the presence of 1 mM IPTG and 1% 
ethanol was found to result in optimal expression. Initially 1% ethanol was added to increase 
the solubility of the expressed rBACE1-GST fusion protein however it was determined that this 
had the opposite effect. The addition of ethanol during induction is meant to slow down 
bacterial growth, resulting in less protein production and thus less inclusion body formation. 
The addition of 3% ethanol did decrease the amount of insoluble protein while increasing the 
amount of soluble protein indicating that 3% ethanol was sufficient in curbing protein 
production, however this evidently did not result in a complete reduction in inclusion body 
formation due to the presence of the majority of rBACE1-GST in the insoluble fraction.  
 
It was noteworthy that the combination of 0.5 mM IPTG in conjunction with 1% ethanol did 
result in more soluble rBACE1-GST indicating that reducing protein production through 
lowering the amount of induction agent did affect inclusion body formation. The increase in 
insoluble protein as a result of the addition of 1% ethanol could be an indication that E. coli 
growth overnight might mitigate the growth retardation brought about by 1% ethanol and 
without the decreased IPTG, inclusion body formation was unaffected. This condition was 
pursued as it was observed that the insoluble fraction that resulted from this induction contained 
the largest amount of protein compared to any other fraction. These expression conditions were 
done at the cost of incorporating a solubilization and refolding step. Expression of the rBACE1-
GST fusion protein was confirmed with both anti-GST IgY as well as anti-BACE1 IgG 
antibodies. Initial western blot analysis indicated degradation of the fusion protein over the 
course of expression, however, after successful affinity purification of the rBACE1-GST 
protein, this degradation was not observed. It was noted that 100% purity was not achieved as 
established through the detection of residual GST-tag with anti-GST antibodies. As this protein 
was not detected by Coomassie stain, it was determined that the residual GST was present at 
markedly low concentrations, thus indicating high purity of the desired fusion protein. 
 
Both solubilization and refolding of rBACE1-GST were successfully carried out using a 10% 
sarkosyl solution. Other refolding techniques were attempted; however, they were 
demonstrated to be ineffective. Refolding was confirmedviathe presence of protease activity in 
a gelatine gel zymogram. Gelatine gel zymography has not previously been described for 
BACE1 yet provides an inexpensive method to confirm activity. It also allows for the detection 
of dimer formation. The commercially purchased BACE1 produced in HEK-293 cells was 
tested as a positive control to confirm that BACE1 is indeed capable of gelatine degradation. It 
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was noted that the mammalian BACE1 exhibited activity in what was assumed to be a dimeric 
and tetrameric form; however, no activity was detected as a monomer. This is in contrast to 
rBACE1 which only displayed protease activity in its monomeric form. This is in accordance 
with literature as it has been reported that both the cytosolic and transmembrane domains assist 
in dimerization whilst the rBACE1 does not possess these domains (Schmechel et al., 2004). It 
was noted that this method was not viable for screening as the protease activity was unaffected 
by the presence of the known BACE1 inhibitor, Verubecestat. This could potentially be due to 
the Verubecestat being unable to readily access the BACE1 in the zymogram, however this has 
not been reported previously. The activity was not accurately quantifiable either, however it 
was noted that 1 µg of mammalian BACE1 resulted in a distinct band of proteolytic activity, 
whereas 100-fold more rBACE1 was required to achieve a similar level of activity. This is 
likely due to the effect of post-translational modifications on BACE1 proteolytic activity, as it 
has been demonstrated previously that the glycosylations found on mammalian BACE1 are 
required for maximal activity (Huse et al., 2000). It was also further noted that prior to the 
removal of the GST-tag from the recombinant protein, no activity was present indicating the 
tag disrupts access to the rBACE1 active site. As a result, cleavage of the GST-tag was carried 
out prior to all subsequent experiments. This expression and refolding protocol resulted in an 
overall rBACE1 yield 70% higher than the highest reported yield (Tomasselli et al., 2008). 
Most notably, it only requires a 24-hour refolding step as opposed to the 3-4 day refolding steps 
previously described (Tomasselli et al., 2008). Finally, the rBACE1 produced was 
proteolytically active. 
 
A BACE1 expression system was also generated using the mammalian HEK-293 cells. These 
HEK-293 cells were stably transfected with a pcDNA-DEST 40 vector containing the full 
human BACE1 gene with transfection being confirmed by the ability of the HEK-293 cells to 
grow in the presence of G418-containing selection media. A non-truncated form of BACE1 
was expressed in these mammalian cells as the transmembrane and cytoplasmic domains are 
required for transport of BACE1 to the Golgi apparatus. This was done to ensure proper 
localization of BACE1 inside the cells to the lysozomes. It was demonstrated through western 
blot that BACE1 was produced in both non-transfected and transfected variants of the HEK-
293 cells which was expected as BACE1 expression in HEK-293 cells has been reported in 
literature previously (Vetrivel et al., 2011). Transfection with the BACE1-pcDNA-DEST 40 
resulted in a higher expression of the BACE1 protein, with densitometry indicating 60% higher 
production of the 67 kDa BACE1 protein. Two large bands were present in all lysates 
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corresponding to sizes of approximately 30 and 35 kDa respectively, which were detected by 
the anti-BACE1 antibodies.  
 
The rBACE1-GST was confirmed to be antigenic and capable of producing both anti-GST and 
anti-BACE1 antibodies in chickens. The anti-BACE1 IgY antibodies were purified and 
confirmed to bind to both bacterial and mammalian forms of BACE1. Specificity of both the 
anti-GST and anti-BACE1 antibodies were confirmed through western blot analysis. The ability 
to generate both anti-GST and anti-BACE1 antibodies from the same fusion protein indicates 
that neither the GST-tag, nor the BACE1 protein, hinder the immunogenicity of the other. 
Further, the generation of antibodies indicates that the fusion protein is immunogenic without 
the need for the attachment of carrier proteins, likely due to the size of the fusion protein. It was 
however noted that while the concentration of anti-BACE and anti-GST antibodies present in 
the eggs of the immunized chicken increased with each successive immunization, after the final 
immunization, the antibody concentration decreased and then plateaued. The BACE1 produced 
in E. coli cells presented a far less defined band when run on a western blot as compared to the 
HEK-293 BACE1. It was expected that the lack of glycosylations would allow for more binding 
of SDS, which would translate to clearer bands as compared to the glycosylated BACE1 from 
the HEK-293 cells however this did not occur. Furthermore, western blots of the purified 
rBACE1 exhibited smearing at the top of the lane indicating aggregation.  
4.2. Bacterially produced rBACE1 is suitable for compound screening 
In order to accomplish Objective 2 of the study, the potential for rBACE1 thermostability to be 
used as a means to screen for BACE1 ligands needed to be established. This was attempted 
using an in-house library of compounds in a DSF assay using the purified rBACE1. Initially, 
multiple buffers were used in an effort to determine the optimal conditions for the assay with 
PBS at a pH of 7.4 ultimately being selected. The lack of a discernible peak when using AMT 
buffers at the same pH as PBS suggested that either the AMT buffer itself interfered with the 
assay, or more likely, the buffer transfer resulted in protein denaturation. Interference in 
thermostability assays by buffer components has been previously reported (Long and Yang, 
2009), however based on the lack of a defined peak in acetate buffer as well, it  is likely that 
the buffer transfer denatured the protein. Since the purified protein was ultimately purified in 
PBS, using PBS as the assay buffer did not require a buffer transfer step as opposed to the use 
of the acetate and AMT buffers. Since aggregation has been reported as a potential side-effect 
of buffer transfers, which would prevent a peak from forming during the assay, this is likely 
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what occurred (Bondos and Bicknell, 2002). The pH at which the peak was detected, pH 7.4, 
was of interest as a study by Hayley et al. in 2009 demonstrated that BACE1 remains folded at 
pH 7.4 while becoming proteolytically inactive. It was also reported that this inactive form 
possesses a Tm value of approximately 84°C indicating thermostability exceeding 
physiological ranges. The study carried out by Hayley et al. however did not report a specific 
Tm value due to the limits of the circular dichroism technique used. This study successfully 
determined the Tm value of rBACE1 to be precisely 82°C indicating the DSF assay may 
potentially be better suited to studying proteins with abnormally high Tm values. The rBACE1, 
when assayed in PBS exhibited a single state unfolding, demonstrated by the R2 value of the 
plot of  ΔuG˚ against temperature of  > 0.9 (Wright et al., 2017). This single state unfolding is 
in contrast to the findings of Hayley et al., where a two-state transition was observed. This is 
potentially due to the use of a truncated protein as opposed to the full protein utilized by Hayley 
and co-workers. This suggests that the transition states, observed during BACE1 unfolding, 
involve the domains not present in the rBACE1 form used in this study. The thermodynamic 
parameters of rBACE1 unfolding in PBS, namely the ΔuG˚, ΔuS˚ and ΔuH˚, were found to be 
112 ± 0.1 kJ/mol, 1.82 ± 0.002 kJ/mol K and 642 ± 0.7 kJ/mol respectively. These values 
indicate high thermostability which was expected due to the high Tm value of 82 ± 0.21°C. 
Furthermore, these values possess low variances despite the extrapolation of the original data 
over such a large temperature range.  
 
The DSF technique was confirmed to be an effective screening tool through a significant shift, 
with a p-value set to 0.05, in Tm of the recombinant protein in the presence of 1 µM of the 
specific BACE1 inhibitor, Verubecestat. This validated the use of the rBACE1 as a means to 
detect BACE1 binding compounds. Furthermore, the binding of Verubecestat confirmed that 
utilizing the inactive form of rBACE1 at pH 7.4 allowed for detection of catalytic site binding 
molecules. This binding was also confirmed to occur in the presence of 2% DMSO, however 
DMSO lowered the Tm values of BACE1 both in the presence and absence of Verubecestat. 
This was unsurprising as DMSO has been documented to lower reported Tm values in DSF 
experiments, with the maximum suggested DMSO concentration being 2% (Sorrell et al., 
2010). It was also noted that after the addition of either Verubecestat or DMSO, BACE1 
exhibited unfolding characteristics implying the formation of a transition state. As a result, 
thermodynamic parameters could not be accurately predicted. This prevented the calculation of 
the change in ΔuG˚ as a result of ligand binding indicating a limitation of this method of ΔuG˚ 
calculation. After optimization of the DSF experiment, the 50-compound in-house library was 
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screened against the rBACE1 and three compounds produced significant Tm increases in 
rBACE1. These three compounds were, C19 (N-ethyl-N',N'-dimethyl-N-[2-(trifluoromethyl) 
benzyl]-1,2-ethanediamine), C34 (3-cyclopentyl-N-(4-pyridinylmethyl) propenamide) and 
C39 (4-chloro-1-(2-ethoxybenzoyl)-1H-pyrazole). This led further credence to the validity of 
this approach of BACE1 ligand screening as it was capable of detecting novel BACE1 binding 
compounds. 
4.3. In silico BACE1 ligand screening provides comparable findings to in vitro DSF 
screening 
An in silico model of BACE1 was prepared and validated using the Schrodinger Biologics suite 
(2018-2). This was carried out as a means of determining the comparability between in vitro 
screening results from the DSF experiments and in silico docking experiments, as a reliable in 
silico BACE1 model would allow for screening of large compound libraries as a preliminary 
method of high throughput screening. The model was validated by successfully redocking 
Verubecestat into the BACE1 active site. This bound Verubecestat demonstrated a low RMSD 
when compared to the co-crystallized Verubecestat, further, many of the interactions between 
Verubecestat and BACE1 that are known to occur were successfully reproduced by this model. 
This model indicated that 5 of the 50 compounds bind to the BACE1 active site in a way that 
would be conducive to inhibition. Furthermore, two of the three compounds, namely C19 (N-
ethyl-N',N'-dimethyl-N-[2- (trifluoromethyl)benzyl]-1,2-ethanediamine) as well as C34 (3-
cyclopentyl-N-(4-pyridinylmethyl) propenamide), identified by the DSF ligand binding assay 
were identified as binders to the catalytic aspartate dyad of the BACE1 enzyme. The detection 
of both C19 and C34 highlighted as catalytic site binding ligands provided further merit to the 
theory that, whilst the BACE1 is in an inactive form in the DSF experiment, the active site 
remains intact.  
 
The three compounds that were detected by this in silico model that did not bind in the DSF 
experiments are likely false positives. This infers that molecular dynamics simulations would 
be required as a means to filter out false positives. Nonetheless, as a means of high throughput 
screening as a preliminary step, the model is satisfactory as evidenced through the identification 
of both C19 and C34 as BACE1 ligands. Other potential reasons for the discrepancy between 
the DSF and docking results could be that these compounds do indeed bind the BACE1 catalytic 
site; however, either due to insolubility or aggregation, are incapable of binding to the protein 
in solution. This was not further explored however as this insolubility would have reduced their 
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potential as drug candidates as compared to the other compounds that were observed to bind in 
the DSF assay.  
 
The lack of detection of C39 as a BACE1 binding compound further necessitated a search for 
other binding sites present on the protein. Whilst docking of the three binding compounds to a 
detected non-catalytic binding site was also attempted, this investigation indicated that C19 
bound to this site in conjunction with the catalytic site whereas no indication of the binding 
mode of C39 was revealed. Further study of the BACE1 protein surface would therefore be 
required, potentially into the only reported BACE1 allosteric site as binding to this site could 
potentiate the use of C39 as a lead molecule. No binding was detected for C34 to the non-
catalytic site of BACE1 indicating that C34 potentially binds specifically to the active site of 
BACE1. Docking against BACE2 was also carried out with only C19 binding to the BACE2 
active site. The lack of binding of C34 to BACE2 reveals C34 to be specific to BACE1, a 
feature that is valuable for human treatment. The binding of C19 to the BACE2 active site is of 
some concern, not only to its potential as a BACE1 specific ligand, but also to the BACE1 
model Since C19 was detected to bind to all three sites that were tested in this study, it calls 
into question the accuracy of these additional binding site receptor grids. The likelihood of a 
compound binding specifically to two sites on the same protein as well as a site on another 
protein, despite the similarities in the proteins, is unlikely. The BACE1 catalytic site receptor 
did not warrant this concern as it was validated using Verubecestat. Validation was not possible 
for the non-catalytic BACE1 binding site detected using SiteMap however, due to the lack of 
known binding molecules. This lack of validation further necessitates the use of molecular 
dynamics simulations, should this binding site be further explored. 
4.4. Detected compounds bind to BACE1 intracellularly 
Compounds detected through DSF were assayed for the ability to bind BACE1 inside 
mammalian HEK-293 cells using the CETSA. Prior to carrying out the CETSA, the cytotoxicity 
of the test compounds was assayed to ensure toxicity would not interfere with the assay. No 
CC50 value was obtained for any of the test compounds within the concentration range that was 
used, confirming that compound toxicity would not be a confounding variable. Initially the Tagg 
of monomeric BACE1 in the presence of DMSO was determined to be 49.53 ± 0.69°C in 
contrast to the Tm found for rBACE1 during DSF which was 82 ± 0.21°C. It was also noted that 
a CETSA could potentially be carried out using the dimer of BACE1 as this exhibited a clear 
temperature dependent decrease in concentration through the CETSA as well. A smaller 
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temperature range would need to be used however to determine the Tagg of the BACE1 dimer. 
The discrepancy between the two values of the monomeric BACE1, that both give inference to 
a protein’s stability, is due to the difference in the properties that directly contribute to protein 
denaturation and aggregation respectively. The Tm value is based on protein denaturation which 
is determined by the disruption of intramolecular bonds such as internal hydrophobic 
interactions and disulphide bonds while a proteins Tagg is based largely on a protein’s solubility, 
meaning full denaturation and disruption of all intracellular bonds is not required for 
aggregation to occur, and it thus requires comparatively less energy in the form of heat to induce 
aggregation than to fully denature a protein. This relationship between a protein’s Tagg and Tm, 
where Tm is higher than the Tagg has been seen previously in granulocyte colony stimulating 
factor by Robinson and colleagues under several different conditions (Robinson et al., 2018).  
 
After the Tagg for BACE1 produced in HEK-293 cells was determined, the compounds detected 
as BACE1 binders through DSF, namely Verubecestat, C19, C34 and C39, were assayed for 
intracellular binding through the CETSA. Both Verubecestat and C34 resulted in a significant 
increase in the Tagg of BACE1 with Verubecestat resulting in an increase from 49.53 ± 0.69°C 
to 53.27 ± 0.89°C and C34 inducing a shift to 53.09 ± 1.30. Both C19 and C39 conferred no 
significant change to BACE1 Tagg indicating that these compounds are likely not capable of 
reaching BACE1 inside the HEK-293. Verubecestat provided validation of this method of 
screening for intracellular BACE1 ligands. This assay is not amenable to high throughput 
however, solidifying the position of this assay late in the compound screening pipeline. 
Furthermore, it is of note that while the CETSA provides further confirmation that C34 binds 
to BACE1, the CETSA is incapable of detecting inhibition. While assaying for BACE1 
inhibition would be the intuitive next stage of this study, intracellular binding has been 
exploited through the use of PROTAC technology to reduce enzyme concentrations. 
4.5. Compound C34 functions as a viable lead compound for detection of further 
intracellular BACE1 binding molecules 
Due to the confirmed ability of C34 to bind intracellular BACE1, this compound was used as 
the lead compound to screen the Enamine compound database for similar, more complex 
compounds capable of binding BACE1. An iterative screening approach for detection of similar 
compounds utilizing the in silico BACE1 model established in this study was utilized ultimately 
resulting in the detection of a compound exhibiting a Glide score of -10.121. This score was 
65% lower than the Glide score of C34, -6.574. A CETSA was then carried out using this 
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compound, C5064, in an effort to determine if it possessed the ability to bind intracellular 
BACE1. Compound C5064 was confirmed to bind intracellular BACE1 through this assay 
indicating the use of C34 as a lead was successful. Based on the lower Glide score of C5064 
when compared to C34, C5064 is expected to bind BACE1 with greater affinity than C34. This 
compound thereby provides merit to the workflow utilized in this study, validating that the use 
of thermostability as a means of detecting BACE1 ligands is effective.    
4.6.Assessing potential for clinical viability of test compounds using in vivo Danio rerio 
toxicity models 
The toxicity of the test compounds was assessed using a zebrafish model to assay for potential 
viability for use of the compounds as binders of BACE1 in vivo. The test compounds yielded 
an effect on the embryos prior to hatching, demonstrating passage through the chorion. This 
was anticipated due to their sizes being well below the suggested cut off of 3 kDa, as the OECD 
guidelines suggest studies involving compounds greater than 3 kDa require dechorionation to 
ensure compounds are capable of accessing the embryo. The toxicity of each compound was 
determined through the use of a ZFET, allowing for LC50 values to be calculated. It was 
observed that C39 exhibited the highest toxicity levels of the test compounds, with an LC50 
value six times less than that of C19, which was itself five times less than that of C34. With 
regards to the toxicity of C39, it was noted that the in silico analysis predicted the compound 
to be mutagenic. Disruption of DNA may thus be the reason toxicity was observed so early in 
the development of the embryos exposed to C39. It was seen that the LC50 value of C39 was 
lower than 3,4-DCA, a compound utilized as a positive control for toxicity tests due to its high 
toxicity with C19 showing an LC50 value only 25% greater. These low LC50 values in 
combination with their confirmed inability to bind intracellular BACE1, reiterate the lack of 
viability of both C39 and C19 for further study. The LC50 value of C34 was acceptable and 
provided justification for further study into its ability to bind BACE1 in vivo. No LC50 value 
was calculated for C5064 due to limited solubility in the assay buffer however it was seen that 
C5064 was incapable of inducing a toxic effect on the embryos within the limits of its solubility. 
This could be resolved through the dissolution of C5064 in a less toxic organic solvent than 
DMSO, such as polyethylene glycol-400 as potentially this would allow greater concentrations 
of C5064 to be used without the toxic effects of the solvent interfering with the results (Maes 
et al., 2012). No TI could be calculated for any of the other test-compounds indicating that 
while C19 and C39 are highly toxic, they are not classified as teratogens. The teratogenicity of 
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C34 was only observable at concentrations higher than the lethal doses of C19 and C39 
however, indicating the potential for further use of C34 as a means to bind BACE1 in vivo.  
4.7.Conclusion 
A recombinant form of the BACE1 protease was successfully expressed at yields higher than 
those currently found in literature. The protein was confirmed to be in an active conformation 
through the use of a gelatine gel zymogram, a technique which, through this study, has now 
been demonstrated to be a reliable method to confirm BACE1 activity. This pure, active 
rBACE1 was then used to create and optimize a DSF ligand binding assay, which was 
effectively used to screen an in-house compound library. This assay confirmed the use of the 
thermostability of BACE1 as a viable means of screening for BACE1 binding compounds as a 
total of three compounds were detected to bind to the recombinant protein through this assay. 
Molecular modelling was used to dock these ligands in silico, against a validated model of 
BACE1, whereby it was indicated that two of the three compounds bound to the active site, 
whereas the third compound possibly bound to an allosteric site. The recombinant BACE1 
protein was also capable of inducing the production of antibodies in chickens, which were 
capable of detecting mammalian BACE1, expressed in a transfected HEK-293 cell line. 
 
A CETSA to detect BACE1 ligands was successfully carried out and validated through the 
confirmation of binding by Verubecestat, with C34 being demonstrated to bind BACE1 
intracellularly. Compound C34 was used as a lead compound to screen the Enamine Real 
database of compounds using the in silico model of BACE1 established in this study. Through 
this method C5064 was identified as a potential BACE1 binding compound. The ability of 
C5064 to bind BACE1 intracellularly was then confirmed using the CETSA once again with 
this discovery providing further validation of the successful establishment of a pipeline for 
screening for BACE1 ligands primarily utilizing the thermostability of BACE1 as a means to 
detect ligand interactions. This successfully confirmed the hypothesis that the CETSA could 
indeed be used as a tool to identify BACE1 ligands. This also fulfilled the aim of the project, 
of thoroughly assessing the thermostability of BACE1, through the determination of the Tm, 
Tagg, standard Gibbs free energy, entropy and enthalpy of unfolding as well as identifying that 




4.8. Further Studies 
A FRET assay could be made and used to assess if C19, C34 and C39 can inhibit BACE1 
activity. Confirmed inhibitors could then be optimized using QSAR to improve their inhibitory 
capabilities. Binding modes of these compounds could also be confirmed using X-ray 
crystallography. With regards to compound C5064, further study could be carried out to 
ascertain its toxicity and teratogenicity in the zebrafish model. Furthermore, C5064 and C34 
could be used as leads to screen for more similar compounds in an attempt to identify more 
intracellular BACE1 binding molecules, potentially with greater solubility than that of C5064. 
Finally, the development of PROTACs using C34 and C5064 could be explored as possible 
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Figure B.1: Map of restriction enzyme cleavage sites found in the BACE1 insert derived from GenBank 






     




Table C.1: Analysis of protease cleavage sites found in the BACE1 peptide sequence 
carried out using the online PeptideCutter tool (Swiss Institute of Bioinformatics, 
Switzerland). 
Protease Number of Cleavage sites 
Arg-C proteinase 25 
Asp-N endopeptidase 25 












Chymotrypsin-high specificity (C-term to 
[FYW], not before P) 45 
Chymotrypsin-low specificity (C-term to 





Factor Xa 0 
 
104 
Formic acid 25 
Glutamyl endopeptidase 27 
Hydroxylamine 2 
Iodosobenzoic acid 10 
LysC 11 
LysN 11 
NTCB (2-nitro-5-thiocyanobenzoic acid) 11 
Pepsin (pH1.3) 96 
Pepsin (pH>2) 127 
Proline-endopeptidase 3 
Proteinase K 239 
Staphylococcal peptidase I 25 








Figure D.1: Sequence alignment of sequenced BACE1 insert against human BACE1 gene with identical 






Figure E.1: Reference standard curve for the Bradford assay. Bovine serum albumin standards ranging from 
50 to 500 µg/ml were mixed 1:9 with Bradford reagent. Absorbance at 595 nm was measured. The equation for 

































Figure F.1: Reference standard curve for the calculation of molecular weights of proteins separated using 
sodium dodecyl sulphate gel electrophoresis. Generated by measuring the distance travelled by each protein in 
the molecular weight marker, plotted against the log(molecular weight) of each protein band. 
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